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ABSTRACT
Partial Characterization of the Antimicrobial Activity of CCL28
Bin Liu
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
This research focuses on the antimicrobial activity of the mouse chemokine CCL28. In
addition to their well characterized chemotactic activity, many chemokines have been shown to
be antimicrobial in vitro, including the mucosally expressed chemokine CCL28. I have
investigated the primary sequence features required for antimicrobial activity, salt sensitive
nature of killing/binding mechanism, and in vivo microbial interactions of CCL28. Through the
use of protein mutation and expression techniques, I have shown that the holoprotein (108 amino
acids) is necessary for full antimicrobial activity of CCL28. Furthermore, the C terminal region
of CCL28 is essential for microbial killing as an almost complete loss of antimicrobial activity is
seen following the removal of the C terminal 24 amino acids. The positively charged amino acids
of the C-terminus directly contributed to the antimicrobial activity of CCL28. These experiments
are the first to investigate the role of primary structure on the killing activity of an antimicrobial
chemokine. Using flow cytometry analysis, I found that the salt-sensitive nature of CCL28
killing activity corresponds to its binding ability. Additionally, I have shown direct evidence for
in vivo interaction between commensal bacteria and endogenously expressed CCL28 in the
mouse large intestine. This interaction may directly correlate to the in vivo antimicrobial activity
of CCL28. Lastly, I have begun to generate a CCL28 knockout mouse model to directly address
the in vivo antimicrobial activity of CCL28. Vector construction and ES cell targeting by the
vector has been completed, chimeric mouse generation remains to be done. This work represents
the first systematic study of antimicrobial chemokine function. This work extends our
understanding of antimicrobial proteins and their role in innate immune protection of the host
and provides guidance for making better alternative antimicrobials.
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Chapter 1: Immune protection, antimicrobial peptides and chemokines

Introduction

We are constantly exposed to microorganisms. A vast number of microorganisms inhabit
the surface of our skin and mucosal tissues. Usually, these commensal microorganisms are not
harmful, but in fact are often beneficial to us by competing against harmful invaders and
providing necessary nutrients, such as vitamin K, to our bodies. However, these commensal
microorganisms can be harmful if our mucosal barriers are damaged or our immune system is
depressed. Some other microorganisms are considered pathogens because they have evolved
specialized mechanisms to invade our tissues and circumvent our defense mechanisms.
Protection from pathogenic and commensal microbes is achieved through immunity.
Simply put, immunity is the ability of a living organism to protect itself from foreign invaders.
Our immune system consists of a wide variety of mechanisms including physical barriers, such
as skin, to shield the organism, and biological or chemical components to kill the
microorganisms directly. Some immune mechanisms are constitutively active, whereas others are
inducible upon invasion by pathogens. Vertebrates have evolved complex immune systems
which include a wide variety of molecules and cells for sensing, signal transduction, antigen
processing, cell differentiation, and finally neutralizing and destroying invading microbes.
Understanding the mechanisms of immunity is very important. Our health depends on a
proper functioning immune system. But the mechanisms used to destroy foreign invaders can
also cause damage to our body. The efficient treatment of diseases requires understanding the
infectious agents as well as the specific immune response to a given pathogen.
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Vertebrates share several commonalities in immune function. All multiple celled
organisms have native immunity, also called innate immunity. Vertebrates have also evolved a
more complex and effective way to fight microbial invasion, which is referred to adaptive
immunity. Although innate and adaptive immunity are often presented as separate entities, it is
important to recognize that these two branches of the immune system must work together to
achieve optimal host protection. Additionally, many cells and proteins of the immune system
have roles in both innate and adaptive immunity.

Innate immunity

Innate immunity is the first line of protection that exists before an infection. It is an
ancient defense mechanism shared by all life kingdoms. Cells and molecules of the innate
immune system have the ability to distinguish host cells from foreign infectious agents by
recognizing conserved molecular patterns which exists in microorganisms but not in host cells.
These cells and molecules can be activated rapidly after encountering microorganisms. However,
their efficacy is usually not improved after they encounter the same microorganism at a later date,
which is the case with adaptive immunity.
The physical barriers of skin and other mucosal tissues are the front line of innate
immunity. Epithelial surfaces can prevent microorganism invasion. Importantly, these “front
line” tissues of the immune system can synthesize and secrete antimicrobial peptides (AMPs) to
kill microorganisms directly. Three types of well-characterized antimicrobial peptides protect
mucosal tissues (De Smet and Contreras 2005; Selsted and Ouellette 2005; Doss, White et al.
2010; Bevins and Salzman 2011). The first type of AMPs is defensins, which are grouped into αand β-defensins based on their structure. The second type of AMPs expressed by epithelial cells
2

is cathelicidins, which have the cathelin domain (Zanetti, Gennaro et al. 1995). The third type of
AMPs is the histidine-rich peptides, histatins (Edgerton, Koshlukova et al. 1998; Peters, Zhu et al.
2010).
If microorganisms penetrate epithelial barriers and enter into tissues, they are often
intercepted by tissue resident immune cells: macrophages, immature dendritic cells, and mast
cells. Macrophages and immature dendritic cell are professional phagocytic cells. They have
phagocytic receptors to recognize microorganisms directly or to recognize opsonized
microorganisms that have been coated by soluble molecules such as complement. These
phagocytes contain phagolysosomes. Matured phagolysosomes contain pathogen degrading
enzymes, antimicrobial peptides, and reactive oxygen and nitrogen species which kill
internalized microorganism. Cells of the innate immune system also often express Toll-like
receptors or the more widely expressed intracellular sensors NOD1, NOD2 and NALP3 which
sense microbial invasion. Activation of these receptors results in the synthesis and secretion of
proinflammatory cytokines by mast cells and macrophages to initiate an inflammatory response.
These cytokines can further attract more macrophages and also activate them. Chemotactic
cytokines, known as chemokines, are important players in the attraction and extravasation of
leukocytes to sites of infection in both the innate and adaptive immune response. Following the
rapid innate immune response, T cells and B cells are activated and contribute to adaptive
immunity.

Adaptive immunity

Adaptive immunity responds slower than innate immunity. It has an almost unlimited
ability to recognize different microbial antigens in a highly specific manner. Adaptive immunity
3

is highly efficient in clearing and preventing infection upon a re-encountering of a specific
pathogen. T cells and B cells are the two main components of adaptive immunity.
Both B cells and T cells use their cell receptors to recognize antigens. The ability of B
cells and T cells to recognize largely different antigens is endowed by the tremendous diversity
of receptors which are generated by genetic recombination during their development.
T cells are pivotal to adaptive immunity. Naive T cells (which have matured in the
thymus) recirculate through the secondary lymphoid tissues where they encounter and interact
with antigen presenting cells that have ingested microbes or other debris and presented those
antigens on their surfaces. Responding T cells proliferate and differentiate into different types of
effector T cells. CD4 cells, one subset of T cells, regulate other immune cells of the body.
Conversely, CD8 T cells function by directly killing infected host cells.

Antimicrobial peptides

Antimicrobial peptides (AMPs) are an important weapon for host defense against
microbial invasion. These peptides are used by many different life forms including plants and
mammals (De Smet and Contreras 2005; Selsted and Ouellette 2005). Almost all living
organisms, ranging from vertebrates to bacteria, utilize AMPs to defend against microbial
invasion (Giangaspero, Sandri et al. 2001; Zasloff 2002). Among the AMPs identified, defensins,
cathelicidins and histatins have been the best-studied (De Smet and Contreras 2005).
Defensins are expressed by different mucosal tissues and immune cells. Paneth cells,
found in the small intestines, and neutrophils express α-defensin while many mucosal epithelial
cells express β-defensin (De Smet and Contreras 2005). Defensins are very effective at killing
microbes in vitro. Knockout/knockin mouse models have confirmed the in vivo antimicrobial
4

activity of defensins (Wilson, Ouellette et al. 1999; Salzman, Ghosh et al. 2003). Crohn’s disease
in humans is believed to be initiated by the lack of Paneth cell differentiation or having fewer
copies of the β-defensin gene (Wehkamp, Schmid et al. 2005). Defensins are also related to
cancer. For example human β-defensin-1, which is produced by the epithelial cells of the genitalurinary tract, the skin, the respiratory tract, and the oral cavity, has depressed expression in most
renal and prostate cancers (Valore, Park et al. 1998; Dale and Fredericks 2005). Correspondingly,
over expression of this gene in bladder cancer and renal cancer has been shown to inhibit cancer
cell proliferation and to result in cancer cell apoptosis (Sun, Arnold et al. 2006). Interestingly
defenisins also have the ability to attract many types of immune cells (Territo, Ganz et al. 1989;
Chertov, Michiel et al. 1996; Yang, Chertov et al. 1999; Oppenheim, Biragyn et al. 2003; Jin,
Kawsar et al. 2010), which may partly explain their function in cancer suppression.
In the cathelicidin group of antimicrobial peptides, only one molecule, LL-37, has been
described in humans (Gordon, Huang et al. 2005). Mice with the homolog of LL-37 knocked out
are more susceptible to skin infection by group A Streptococci and urinary tract infection by E.
coli (Chromek, Slamova et al. 2006). The expression of this molecule can be further induced in
skin and lung after inflammation to more than ten-fold (Zasloff 2002). It can also bind to, and
neutralize the LPS endotoxin (Bals, Weiner et al. 1999). Similar to defensins, LL-37 also acts to
attract neutrophils and mast cells by binding to cellular receptors (Schiemann, Brandt et al. 2009).
The histatin group of AMPs is thought to be involved in maintaining oral health.
Histantins protect oral tissues by killing Candida albicans (Edgerton, Koshlukova et al. 1998;
Peters, Zhu et al. 2010). Multiple types of histatin exist, and the most effective one is histatin 5.
They are secreted by the submandibular, sublingual, and parotid glands and are present in saliva
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(De Smet and Contreras 2005). The in vivo antimicrobial activity of histatin 5 has been shown by
an ex vivo murine model (Peters, Zhu et al. 2010).
There are also several other antimicrobial proteins identified in humans, including many
ribonucleases (Harder and Schroder 2002; Dyer and Rosenberg 2006). For most of these
ribonucleases, their antibacterial or antiviral activity is independent of their RNase activity,
which can degrade microbial RNA. For example, RNase 7 is effective at nano-molar
concentrations and kills P. aeruginosa without requiring its RNase activity (Huang, Lin et al.
2007). This kind of antimicrobial peptide is produced by eosinophils, neutrophils, and skin
keratinocytes (Harder and Schroder 2002; Dyer and Rosenberg 2006). Other examples of
antimicrobial proteins include Psoriasin and lysozyme from skin and air-way epithelium,
dermcidin from sweat, phospholipase A2 from tears, histones from neutrophils, and plateletderived factors from platelets (Buckland and Wilton 2000; Schittek, Hipfel et al. 2001; Kim, Cho
et al. 2002; Tang, Yeaman et al. 2002; Harder, Glaser et al. 2007). Additionally, a ubiquitously
expressed, multiple-functional, cellular prion-related protein (PrPc) has recently been shown to
have broad-spectrum antimicrobial activity (Pasupuleti, Roupe et al. 2009). These examples
demonstrate that the antimicrobial activity of many AMPs is secondary or in addition to other
protein functions.
Most AMPs are cationic. It has been proposed that the mechanism for the antimicrobial
activity of defensins and other AMPs involves the interaction between the positively charged
regions of these peptides and the negatively charged microbial cell membrane resulting in
membrane lysis and cell death. Segregation of patched hydrophilic and hydrophobic residues to
form an amphipathic structure is also important for AMP activity. And such a structure can be
induced after the interaction with a membrane (Huang 2000; Giangaspero, Sandri et al. 2001;
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Shai 2002). In bacteria, LPS and teichoic acids are negatively charged. The phosphomannan
component of fungi is also negatively charged and thought to be a target of AMPs (Ballou 1990;
Yeaman and Yount 2003).
Other AMPs do not lyse the microbial cell membrane but bind to the cell wall and are
imported to the mitochondria where they inhibit ATP production. This has been shown to be the
case for AMPs such as histatin 5 and human β-defensin 2 (Li, Sun et al. 2006; Vylkova, Nayyar
et al. 2007). Additionally, some AMPs may interfere with extracellular molecule synthesis, such
as in the cell wall, or intracellular molecule functions (Yeaman and Yount 2003; Schneider,
Kruse et al. 2010). Still other AMPs bind to iron or sequester other trace elements from bacteria,
such is thought to be the case for skin psoriasin (Glaser, Harder et al. 2005).
Through evolution some microorganisms have acquired effective strategies to evade
AMPs. This resistance to AMP-mediated death can be either inherent or inducible. One
mechanism commonly used by bacteria is the incorporation of positively charged components
into the cell wall or cell membrane, thus making them less negatively charged and less of a target
for the positively charged AMP (Peschel, Otto et al. 1999; Cao and Helmann 2004). Such
mechanisms have been described in Staphylococcus aureus and Bacillus subtilis. A well
characterized model of this is the bacterial PhoP/PhoQ two-component system. This two
component system is used to remodel the microbial cell membrane to form a less negatively
charged structure. This system is inducible following the microbe’s encounter with the AMP. It
has been shown in Salmonella and E. coli that this induction is accomplished through addition of
aminoarbinose to the phosphate group or acylation of lipid A in the LPS (Gunn, Ryan et al. 2000;
Starner, Swords et al. 2002).
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The PhoP/PhoQ system can also induce the expression of outer membrane proteases,
which degrade AMPs directly, in many species of bacteria including the PgtE protein expressed
by Salmonella, the Pla protein by Yersinia, and the Sap protein by C. albicans (Guina, Yi et al.
2000; Meiller, Hube et al. 2009). Streptococci use M protein or SIC protein to inactivate AMPs
by binding to them (Frick, Akesson et al. 2003; Frick, Schmidtchen et al. 2003; Nizet 2006).
Similarly, Pseudomonas aeruginosa and Enterococcus faecalis can be induced to express
proteinases which degrade proteoglycans, and then this free proteoglycan binds AMPs (Park,
Pier et al. 2001). Other bacterial evasion strategies include the formation of capsules or biofilms
to shield them from AMPs. Additionally, it has been demonstrated that Yersinia utilizes efflux
pumps to expel AMPs out of the cell membrane (Bengoechea and Skurnik 2000). Finally, some
bacteria have been shown to actively downregulate the expression of host AMPs (Islam,
Bandholtz et al. 2001).
Due largely to the excessive use of conventional antibiotics, multiple-antibiotic resistant
strains of pathogens have become an increasingly prevalent problem. Although some bacteria
have evolved AMP avoidance mechanisms, due to the manner in which AMPs typically
recognize and kill microbes, bacteria have generated less resistance to AMPs than to
conventional antibiotics. The effectiveness and specificity of AMPs makes these molecules good
candidates as alternative antimicrobials. As such, AMPs are of great interest in research and for
use as clinical therapeutics.
Understanding the antimicrobial elements present in AMPs can provide guidance in
engineering synthetic therapeutic drugs. To this end, primary, secondary, and tertiary structure
elements important for antimicrobial activity of AMPs have been extensively explored (Pazgier,
Prahl et al. 2007; Zou, de Leeuw et al. 2007; Jiang, Vasil et al. 2009). In studies of AMP
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molecular structure it has been found that AMPs can adopt α-helix, β-sheet, or a mixture of these
structures. Importantly, some AMPs may be unstructured in solution, however, when they are
incubated with Tetrafluoroethylene, which mimics interaction with a bacterial membrane, an αhelical conformation is formed (Campagna, Saint et al. 2007). Study of α-defensins with model
membranes has also shown that the presence of an organic phase is required for a conformational
change in which the hydrophobic group of the peptide is exposed (Lourenzoni, Namba et al.
2007). Although appropriate structure is often important in AMP function, a fixed tertiary
structure is not always required for antimicrobial activity. For example, deletion or substitution
of cysteins in β-defensin-3 or in tachyplesin l does not affect their antimicrobial activity (Wu,
Hoover et al. 2003; Kluver, Schulz-Maronde et al. 2005; Ramamoorthy, Thennarasu et al. 2006).
On the other hand, disulfide bridges may be important in protecting the AMPs from degradation
by peptidases and thus are necessary for antimicrobial activity in vivo (Tanabe, Ayabe et al.
2007). Dimerization can also contribute to antimicrobial activity. For example, dimerized βdefensin has a much higher activity than its monomer (Campopiano, Clarke et al. 2004). Human
β-defensin-3 has the highest antimicrobial activity among all defensins, which may be explained
by the fact that it can form dimers in solution even at low concentrations (Schibli, Hunter et al.
2002). Human α-defensin also mediates membrane pore formation in the form of a dimer (Zhang,
Lu et al. 2010).

Chemokines

Chemokines are a group of small proteins (5-20 kDa) that are critical mediators for
recruiting specific subsets of leukocytes to lymphoid tissues (constitutive homing) as well as
sites of inflammation (inducible homing) via their corresponding chemokine receptor (Butcher
9

and Picker 1996; Lukacs 2001; Esche, Stellato et al. 2005; Allen, Crown et al. 2007). They play
important roles in both innate and adaptive immunity. Based on the amino-terminal conserved
cysteine arrangement, chemokines have been classified into CXC, CC, C, and CX3C subgroups
(Zlotnik and Yoshie 2000). Chemokine receptors are seven-transmembrane G-protein-coupled
receptors, which are named based on the chemokines they recognize. There are about 50
chemokines and 20 receptors that have been identified in humans to date (Allen, Crown et al.
2007).
Chemokines are highly variable in primary sequence but are very similar in tertiary
structure, starting at the N terminus with three anti-parallel β-sheets followed by a C-terminal αhelix. Chemokines form two or three intramolecular disulfide bonds. The interactions between
chemokines and chemokine receptors are usually both specific and redundant. The N-terminal
amino acids are thought to be critical for specific receptor binding (Ott, Lio et al. 2004; Prado,
Suetomi et al. 2007), whereas the α-helix of the C-terminus is thought to serve as a structural
scaffold and the C-terminus of some chemokines can be switched between chemokines without
loss of receptor specificity (Rajagopalan and Rajarathnam 2006).
Chemokines sometimes also require binding to glycosaminoglycans (GAGs) for in vivo
function. This binding is thought to provide a platform for the interaction between chemokine
and chemokine receptor and is resistant to the shearing forces of blood flow. GAGs are highly
heterogeneous, extracellular molecules. Different cell types often express different types of
GAGs which may be important in mediating chemokine function (Handel, Johnson et al. 2005).
The exposed residues, usually positively charged arginine, lysine, and histidine in the loop
regions of β-sheets and α-helix, are responsible for binding to GAG and it is thought that the
binding between some chemokines and some GAGs is highly specific (Johnson, Proudfoot et al.

10

2005; Severin, Gaudry et al. 2010). Many chemokines are known to form dimers or other
oligomers, especially when binding to GAGs (Handel, Johnson et al. 2005; Johnson, Proudfoot
et al. 2005). This oligomerization has been shown to be necessary for the function of some
chemokines in vivo (Baltus, Weber et al. 2003; Proudfoot, Handel et al. 2003).
The main function of chemokines is thought to be the chemoattraction of leukocytes.
Leukocyte accumulation to tissues is a multiple-step cascade of events, in which chemokines
play an important role in determining the specificity and activation of the signal required for
immune cell migration. In inflammatory conditions, cytokines induce the expression of selectins,
integrin receptors (addressins) on endothelial cells, and chemokines. The type of chemokine
expressed will determine the type of circulating cell that will be recruited to a given tissue. After
extravasation from the blood vessel into the tissue, leukocytes migrate to specific
microenvironments by following chemokine gradients.
Chemokine mediated phagocytic cell and lymphatic cell extravasation is very important
for the host to be able to fight infection. For example, mice deficient in CXCR2 or its receptor
CCR1, are highly susceptible to S. aureus infection in the brain and to coronavirus infection in
the central nervous system (Kielian, Barry et al. 2001; Hickey, Held et al. 2007). Constitutively
expressed chemokines mediate leukocytes homing, recirculation, and development. Chemokines
CCL19 and CCL21 mediate naïve B cell, naïve T cell, and mature dendritic cell migration to the
secondary lymphoid organs (Ono, Nakamura et al. 2003). These chemokines are important in
maintaining homeostasis in the immune system. Recently, chemokines have been recognized to
be involved in many other biological process, such as lymphocyte differentiation, cell
proliferation, angiogenesis, and tumor immune escape (Esche, Stellato et al. 2005; Pivarcsi,
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Muller et al. 2007; Keeley, Mehrad et al. 2010; Struyf, Salogni et al. 2010). All of these
functions reflect the key role of chemokines in immune processes.
In addition to their function in cell homing and migration, the majority of chemokines
have been shown to exhibit direct antimicrobial activity in vitro (Cole, Ganz et al. 2001; Yang,
Chen et al. 2003). However, it is not very clear whether these proteins play a direct antimicrobial
role in vivo. Some chemokines have been shown to have broad antimicrobial activity against
Gram-positive bacteria, Gram-negative bacteria, some fungi, and enveloped viruses (Takahata,
Takada et al. 2003; Yang, Chen et al. 2003; Linge, Collin et al. 2008). However, different
chemokines exhibit different antimicrobial potencies and spectra. Just like other AMPs, their
antimicrobial activity is salt-sensitive. With an increase in salt concentration, the killing activity
and the binding of chemokines to bacterial membranes decrease (Hieshima, Ohtani et al. 2003;
Linge, Collin et al. 2008).
Like many other AMPs, antimicrobial chemokines are also cationic, suggesting that they
may use the same antimicrobial mechanism as defensins. As for their structures, both human
defensins and chemokines have three antiparallel β-sheets and one α-helix. It is postulated that
the C-terminus of chemokines is responsible for the antimicrobial activity (Cole, Ganz et al.
2001). For example, the C-terminal helix of CCL20 is solely responsible for its full antimicrobial
activity, even though the N- terminus also contains cationic residues (Hoover, Boulegue et al.
2002; Chan, Hunter et al. 2008). CXCL8 (interleukin-8) is not antimicrobial, but its C-terminus
alone is antimicrobial (Bjorstad, Fu et al. 2005). The antimicrobial activity of LL-37 and CXCL
chemokine platelet-derived factor thrombocidin are derived from the cleavage of their parent
forms in vivo. However, the N-terminus of CXCL6 has higher antimicrobial activity than it Cterminus, whereas the holoprotein has the highest antimicrobial activity (Linge, Collin et al.
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2008). Tertiary structure comparison between some antimicrobial chemokines and nonantimicrobial chemokines has revealed that some antimicrobial chemokines have a large,
positively charged electrostatic patch on their surfaces (Yang, Chen et al. 2003). It is not known
if this is true for all chemokines or other cationic AMPs.
Recently, evidence has shown that chemokines and defensins are convergent in two
functions: chemotaxis and antimicrobial activity. It is a great advantage for the immune system if
one molecule can kill the microorganisms directly and at the same time also attract immune cells
for additional aid in microbial destruction. Both α-defensin and β-defensin can attract dendritic
cells, monocytes, and/or T-cells, by using the same chemokine receptor (Territo, Ganz et al.
1989; Chertov, Michiel et al. 1996; Yang, Chertov et al. 1999; Niyonsaba, Iwabuchi et al. 2002;
Yang, Biragyn et al. 2002; Rohrl, Yang et al. 2010; Rohrl, Yang et al. 2010). Defensins can also
attach to GAGs as chemokines do (Seo, Blaum et al. 2010).
Chemokines and defensins kill microorganisms only at relatively high concentrations. In
one way, this may be beneficial for the host. The surface of mucosal tissues is often constantly
inhabited by commensal bacteria, which are vital to our health. Those bacteria may not be killed
by the AMPs because of the low concentration of AMPs diffused from underlying cells. Only if
the microbe has the ability to firmly attach and penetrate the cell surface will they encounter high
concentrations of AMPs, which will kill them. Pathogen invasion also results in inflammation
and upregulation of AMP expression (Egesten, Eliasson et al. 2007). Both chemokines and
defensins may kill the microorganisms at the site of infection and diffuse to attract leukocytes.
Even though the in vivo antimicrobial function for many chemokines is unknown, based on the
expression level and location, a few of those chemokines have been proposed to play an
important role in innate immunity against bacterial invasion (Egesten, Eliasson et al. 2007;
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Maerki, Meuter et al. 2009; Kotarsky, Sitnik et al. 2010). For example, CCL6, is highly
expressed in the small intestine and large intestine, and expression can be stimulated by LPS in
vivo. CXCL14 is the highly expressed in epidermis and dermis and is thought to help protect
human skin from microbial colonization (Yeaman, Yount et al. 2007). What’s more, antibodymediated neutralization of CXCL9, 10, and 11 was found to increase the susceptibility of mice to
inhalation anthrax, suggesting an AMP role in vivo for this chemokine (Crawford, Burdick et al.
2010).
Antimicrobial chemokines are potential candidates for alternative antimicrobials.
Discovery of effective alternative antimicrobials is a long-term task. The emergence of multipleantibiotic resistant pathogens makes it more urgent than ever before. Studying the antimicrobial
mechanisms of chemokines can be beneficial in effective drug design. However, identifying the
antimicrobial functional elements and elucidating the antimicrobial mechanisms of chemokines
has just begun. The next fundamental question that must be answered is which antimicrobial
chemokines play an antimicrobial role in vivo. Finding out the antimicrobial role of chemokines
will help us to understand how the immune system works. In the next few chapters, I discuss the
different techniques I have used to address some of these questions.
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Chapter 2: Identifying amino acids important for antimicrobial activity of chemokine
CCL28

Introduction

Chemokines are a group of small proteins (5-20 kDa) that play important roles in both
innate and adaptive immunity. These chemotactic proteins play a key role in recruiting
leukocytes to lymphoid tissues (constitutive homing) as well as to sites of inflammation
(inducible homing) (Butcher and Picker 1996; Lukacs 2001; Esche, Stellato et al. 2005; Allen,
Crown et al. 2007). In addition to their function in cell homing and migration, several
chemokines have been shown to exhibit direct antimicrobial activity in vitro (Niyonsaba,
Iwabuchi et al. 2002; Yang, Chen et al. 2003; Linge, Collin et al. 2008).
The chemokine CCL28 has been shown to selectively attract IgA plasma cells to various
mucosal tissues through interactions with its cognate receptor, CCR10 (Wang, Soto et al. 2000;
Wilson and Butcher 2004). This chemokine has also been shown to exhibit broad spectrum
antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and fungi. The
antimicrobial activity of CCL28 was initially identified due to its homology with the
antimicrobial peptide histatin 5 (Hieshima, Ohtani et al. 2003). Histatin 5, CCL28, and other
antimicrobial peptides (AMPs), such as defensins, often require low salt (non- physiologic)
solutions for maximum antimicrobial activity in vitro. However, mouse models in which
defensin function is inhibited clearly demonstrate an essential antimicrobial role for these AMP’s
in vivo (Wilson, Ouellette et al. 1999; Salzman, Ghosh et al. 2003).
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A mechanism for the antimicrobial activity of defensins and other AMPs has been
proposed in which positively charged regions of these peptides attach or insert into the
negatively charged microbial cell membrane, ultimately resulting in microbial cell death.
Segregation of patched hydrophilic and hydrophobic residues and the formation of an
amphipathic structure may also be important for AMP activity (Huang 2000; Giangaspero,
Sandri et al. 2001; Shai 2002).
Although the antimicrobial activity of several chemokines has been described, very
little is known about the structural requirements needed to facilitate the killing of bacteria by
these proteins. Previous studies have explored the relationship between amino acid sequence and
the antimicrobial function of defensins (Hoover, Wu et al. 2003; Powers 2003; Tanabe, Qu et al.
2004; Wu, Li et al. 2005; Xie, Prahl et al. 2005; Pazgier, Prahl et al. 2007; Taylor, Clarke et al.
2008). When compared with defensins and other AMPs, chemokines are larger in size and have
a more complex structure (Butcher and Picker 1996). No previously reported studies have
explored the role of primary protein structure in chemokine-mediated antimicrobial activity.
CCL28 provides an excellent model to understand the structural requirements for
chemokine-mediated killing. All CC chemokines are thought to have a similar structure (Butcher
and Picker 1996; Shaw, Johnson et al. 2004). The chemokines CCL28 and CCL27 share 31%
identity at the amino acid level and both mediate the migration of lymphocytes via interactions
with the chemokine receptor CCR10 (Homey, Wang et al. 2000). In contrast to CCL28, CCL27
exhibits no antimicrobial activity (Hieshima, Ohtani et al. 2003; Linge, Collin et al. 2008).
Interestingly, these two proteins share high homology at the N-terminus of the protein and low
homology at the C-terminus. Correspondingly, the N-terminus of chemokines has been
implicated in mediating migration, and the C-terminus has been hypothesized to be important for
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antimicrobial activity (Hemmerich, Paavola et al. 1999; Hoover, Boulegue et al. 2002; Ott, Lio et
al. 2004; Chan, Hunter et al. 2008).
To investigate the role of primary protein structure on the activity of the antimicrobial
chemokine CCL28, we used PCR based mutagenesis to generate truncation, deletion, sitespecific substitution, and chimeric mutants of the protein. These mutant proteins were then
assayed in vitro for antimicrobial activity. Results demonstrate that positively-charged amino
acids at the C-terminus of CCL28 significantly contribute to the antimicrobial activity of the
protein. Through the generation of CCL27/CCL28 and CCL5/CCL28 chimeric proteins we also
demonstrate that interactions between the antimicrobial C-terminus of CCL28 with an
appropriate CC chemokine N-terminal domain may be important for the full antimicrobial
activity of CCL28.

Materials and Methods

Reagents and bacteria
Mouse CCL28 recombinant protein was purchased from R&D systems Inc. (Minneapolis,
MN). Two bacteria strains, Staphylococcus aureus (ATCC 29213) and Pseudomonas
aeruginosa (ATCC 10145), were purchased from ATCC (Manassas, VA). Yersina pestis
isolates were kindly provided by Dr. David Erikson (Brigham Young University). All the
bacteria were grown in tryptic soy broth at 37°C (BD Diagnostics, Sparks, MD) until they
reached log phase (OD600 = 0.5~0.6).
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CCL28 primary structure and tertiary structure analysis
CCL28 charge and hydrophobicity profile were analyzed by Emboss and ProtScale,
respectively. CCL28 tertiary structure was predicted by the program 3Djigsaw, based on the
newly published structure of human chemokine CCL27 (Kirkpatrick, et al, 2010), which among
all chemokines, shares the highest homology with CCL28.

Preparation of recombinant mouse CCL28
Recombinant mouse proteins were expressed in E. coli as N-terminal His-tagged fusion
proteins through cloning into the XhoI site of the pET19b expression vector (Novagen, Inc.,
Madison, WI). Briefly, total RNA was extracted from mouse large intestine using Trizol
(Invitrogen, Corp., San Francisco, CA). The mouse CCL28-coding cDNA sequence, without its
signal sequence, was amplified using a pair of primers (CCL28-F and CCL28-R, Table 1), based
on the DNA sequence retrieved from NCBI (NM_020279), and GeneAmp PCR Core Reagents
(Applied Biosystems, Foster City, CA). All the primers used are listed in Table 1. RT-PCR
reaction conditions consisted of 42 °C incubation for 15 min for reverse transcription using
Oligo dT, followed by 95°C for 10 min and PCR cycles at 94 °C for 1 min, 60°C for 1 min, and
72 °C for 1 min for 30 cycles. Following PCR amplification, amplicons (25 µl) were separated
using 2% agarose gels, and purified using Qiagen gel purification kit (Qiagen Inc., Valencia CA).
The purified PCR products were then digested by XhoI and gel purified. The digested PCR
products were ligated into XhoI digested plasmids, and transformed into DH5α E. coli.
Transformants were selected through colony PCR. Plasmids were extracted using a Qiagen
miniprep kit and the correct CCL28 sequence was confirmed through cycle sequencing of all
inserts.
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Preparation of recombinant mouse CCL5 and CCL27
Total RNA extracted from mouse spleen and ear was used to amplify CCL5 and CCL27,
respectively. The primers CCL5-F and CCL5-R were used to amplify the CCL5 gene. Primers
CCL27-F and CCL27-R were used to amplify the CCL27 gene. The same procedure as
described above was used for the digestion, ligation, and transformation. Sequences were
confirmed through cycle sequencing of the inserts.

C-terminal and N-terminal truncation mutants
The primer sequences used to generate truncation, point mutation, and chimera are all
listed in Table 1. To generate successive C-terminus truncation mutants, the common forward
primer, CCL28-F, was paired with the following reverse primers: C-R1, C-R2, C-R3, C-R4, CR5, C-R6, C-R7, C-R8, and C-R9. The N-terminus mutants were generated using the common
reverse primer CCL28-R with primer NF5. The same procedure was used for digestion, ligation,
and transformation, as described above. All sequences were confirmed through cycle sequencing
of the inserts.
Table 1. Primer names and sequences
Primer Name

Sequence (5’-3’)

CCL28-F

GCCGCTCGAGATACTTCCCATGGCCTCCAGCTG

CCL28-R

CCGAGCTCGAGCTAACGAGAGGCTTCGTGCCTGT

CCL5-F

GCCGCTCGAGTCACCATATGGCTCGGACACCAC

CCL5-R

CGAGCTCGAGCTAGCTCATCTCCAAATAGTTGATG

CCL27-F

GTTACTCGAGTTGCCTCTGCCCTCCAGCACT

CCL27-R

CGAGCTCGAGTTAGTTTTGCTGTTGGGGGTTTGAG

C-R1

CCGAGCTCGAGCTAGTGCCTGTGTGTTCCACGTG
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Table 1. Continued
C-R2

CCGAGCTCGAGCTAACGTGTTCTGTGCTTTCTCG

C-R3

CCGAGCTCGAGCTATCTCGTAGTGTGCCCTTTTCTG

C-R3

CCGAGCTCGAGCTATCTCGTAGTGTGCCCTTTTCTG

C-R4

CCGAGCTCGAGCTATTTTCTGTCCTTCCTGCTGGG

C-R5

CCGAGCTCGAGCTAGCTGGGTTGTTTTTTCCCAG

C-R6

CCGAGCTCGAGCTACCCAGAACATACGTTTTCTCTGC

C-R7

CCGAGCTCGAGCTATTCTCTGCCATTCTTCTTTACC

C-R8

CCGAGCTCGAGCTACTTTACCTCTGAGGCTCTCATCC

C-R9

CCGAGCTCGAGCTATCTCATCCACTGCTTCAAAGTACG

NF5

GCCGCTCGAGAAGAAGAATGGCAGAGAAAACG

∆108-F

CACAGGCACGAAGCCTCTTAGCTCGAGGATCCGGCTGCT

∆85-89-F

TCTGGGAAAAAACAACCCAGCGGGCACACTACGAGAAAGCAC

R108/D-F

ACACACAGGCACGAAGCCTCTGATTAGCTCGAGGATCCGGCTGCTAAC

R108/A-F

ACACACAGGCACGAAGCCTCTGCTTAGCTCGAGGATCCGGCTGCTAAC

E105/R-F

ACACGTGGAACACACAGGCACAGAGCCTCTCGTTAGCTCGAGGATCCG

CC/A-F

GAGATACTTCCCATGGCCTCCAGCGCTACTGAGGTGTCTCATCATGTTTCC

CCL5-28-R

TGAGGCTCTCATCCACTGCTTCAAAGTACGTGGGTTGGCACACACTTGGCGGTTCCTTCG

CCL5-28-F

CGAAGGAACCGCCAAGTGTGTGCCAACCCACGTACTTTGAAGCAGTGGATGAGAGCCTCA

CCL27-28-R

GCAGATTCTTCTACGTTTAACATGGACAAACACGACTGCAAGATTGGA

CCL27-28-F

TCCAATCTTGCAGTCGTGTTTGTCCATGTTAAACGTAGAAGAATCTGC

Site-specific mutagenesis for point and deletion mutants
To generate site-specific mutations, the circular PCR method was used. In this method
the entire plasmid containing the mouse CCL28 gene was amplified by Platinum® Pfx DNA
Polymerase (Invitrogen, Corp., San Francisco, CA), and a pair of complementary primers was
used to generate site-specific mutations. The following primers were used (only forward primers
are listed): R108/D-F, R108/A-F, E105/R-F, and CC/A-F. Using the above listed primers, for
each mutation, two PCR reactions (25µl) were set up separately using only one of the
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complementary primers for each. After incubation at 95°C for 5 min, eight PCR cycles were
completed using the following conditions: 94 °C for 1 min, 60°C for 1 min, and 68 °C for 6 min.
The two reactions were then combined, and an additional 16 cycles were performed. DpnI was
then added to the PCR reaction to digest the template plasmid. The DpnI treated PCR reaction
was purified using the Qiagen PCR cleanup kit. The resulting PCR product was then transfected
into DH5α E. coli, and constructs were confirmed by cycle sequencing.

Chimeric mutant preparation
To generate chimeric mutants, a two-step PCR-based method was used. In this method
two PCR reactions were set up: in the first reaction, CCL5 template and CCL5-F and CCL5-28R primers were used, and in the second reaction, CCL28 template and CCL5-28-F and CCL28-R
primers were used. For generation of CCL27 N-terminus and CCL28 C-terminus chimeric
proteins, CCL27 template and CCL27-F and CCL27-28-R primers were used for the first
reaction and CCL28 template and CCL27-28-F and CCL28-R primers were used for the second
reaction. After amplification, the two reactions were gel-purified and combined as template for
PCR of a third reaction using CCL5-F and CCL28-R or CCL27-F and CCL28-R primers. After
purification of the two chimeric PCR products, they were digested and ligated to the pET19b
plasmid, and then transformed into DH5α E. coli. All constructs were confirmed through cycle
sequencing.

Expression and purification of recombinant mouse CCL28 protein and its mutants
All engineered plasmids were transformed into BL21 (DE3) bacterial cells, and a single
colony was selected and inoculated into a test tube containing 2ml Luria broth. These cells were
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then grown to an optical density (OD600) of 0.6 at 37°C and then transferred to 50 ml of Luria
broth. The cells were grown at 37°C until they reached log phase (OD600≈0.8), at which time
recombinant protein production was induced by adding isopropyl-β-D-1-thiogalactopyranoside
(IPTG) to a final concentration of 0.5mM. The culture was then incubated for 6 hours at 30°C.
Cells were lysed and recombinant protein was purified by nickel-nitrilotriacetic acid resin
according to the manufactures protocol (His SpinTrapTM, GE Healthcare, Buckinghamshire, UK).
The purified His-tag fusion protein solution was then dialyzed against 1mM Tris-HCL buffer
(pH 8.0) overnight in a 5L beaker with three buffer changes. The dialyzed protein solution was
then centrifuged to remove any precipitated protein. The purity of the protein was confirmed by
visualizing the protein following electrophoresis on a 16% SDS-PAGE gel. The concentration of
the protein was determined by Bradford assay (Thermo, Sci., Rockford, IL).

Antimicrobial activity assays
A slight modification of the standard colony forming assay was used to test the
antimicrobial activity of mutant peptides against Staphylococcus aureus and Pseudomonas
aeruginosa (Hieshima, Ohtani et al. 2003). Briefly, bacteria were grown at 37°C in tryptic soy
broth to mid log phase (OD600=0.5) and then diluted to 106 colony forming units/ml in sterile
Tris-HCl buffer (1mM, pH 8.0) supplemented with 1% (v/v) of tryptic soy broth. Bacteria were
incubated with recombinant chemokines in 60 µl of buffer in a 96 well plate for 30 min at 37°C
with shaking. Chemokines were 2-fold serially diluted to concentrations ranging from 2 µM to
0.125 µM in 50 µl Tris-HCl. Bacteria, in a volume of 10 µl were then added into each well.
Assays using each chemokine were repeated three times. Following the incubation of
recombinant proteins with bacteria, the samples were spread on to tryptic soy agar plates. After
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incubation of the plates at 37°C for 12- 20 hr, surviving bacteria were counted as colony forming
units/ml.

Results

Recombinant CCL28 exhibits antimicrobial activity
In establishing our model system we first sought to demonstrate that our in-house protein
production and purification procedures yielded CCL28 that effectively killed bacteria, as has
previously been demonstrated for commercially available CCL28 (Hieshima, Ohtani et al. 2003).
To determine the antimicrobial activity of our recombinant proteins, in-house produced CCL28
and CCL5 proteins were used in antimicrobial assays, as described in Materials and Methods. In
preliminary experiments we found that Staphylococcus aureus and Pseudomonas aeruginosa
displayed slightly different sensitivities to CCL28-mediated killing (data not shown). In all
subsequent experiments a final protein concentration of 1µM for Staphylococcus aureus and
0.5µM for Pseudomonas aeruginosa was used. Antimicrobial assays confirmed that
recombinant CCL5 showed no antimicrobial activity, when compared to BSA or buffer only
controls. In-house recombinant CCL28 demonstrated potent antimicrobial activities, similar to
commercially produced CCL28 (Fig. 1).

The C-terminal region of CCL28 is indispensable for optimal antimicrobial activity
It has previously been suggested that the 28 C-terminal amino acids of CCL28 play a key
role in the observed antimicrobial properties of this chemokine (Hieshima, Ohtani et al. 2003).
In an effort to more precisely define which regions of the protein are essential for antimicrobial
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Figure 1. Recombinant mCCL28 exhibits potent antimicrobial properties, but mCCL5 does not.
The antimicrobial activity of mCCL28, CCL28 (R&D), mCCL5, BSA and buffer controls
demonstrate that in-house, full length CCL28 exhibits microbial killing which is comparable to
commercially produced CCL28. S. aureus (A), and P. aeruginosa (B), were exposed to the
substances listed in the X axis, and surviving bacteria were quantitated as CFU/ml (Y-axis). Each
assay was run in triplicate. Data shown are means ± SEM.
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activity, we produced several mutant versions of CCL28 through successive C-terminal
truncations. The expression and purification of those mutant proteins are described in the
method. The Ni-column purified mutant proteins were visualized by SDS-PAGE (16%). Both the
expression and the purity of those proteins were good (Fig. 2A). These truncated recombinant
proteins were then assayed for antimicrobial activity. The antimicrobial activity of CCL28
generally decreased as progressively larger sections of the C-terminal region were deleted.
Following truncation 5 (truncation of 24 C-terminal amino acids) the antimicrobial activity of
CCL28 was largely abrogated, with bacterial survival increasing 10 fold in experiments using the
C5 truncation compared to the C4 truncation of the CCL28 protein (P=0.007 and 0.039 for
experiments using S. aureus and P. aeruginosa, respectively). These results confirm that the C
terminal region of CCL28 is essential to the antimicrobial activity of CCL28. Furthermore, these
results demonstrate that amino acids 85-89 (contained in the C4 mutant protein) are key to the
antimicrobial activity of CCL28. Although differences in the antimicrobial activity of full length
CCL28 and truncations C1-C4 were not all strongly significant (P values ranging from 0.1 to
0.04) a consistent pattern was observed in experiments using both S. aureus and P. aeruginosa in
which the antimicrobial activity of mutations C1-C3 gradually decreased and the antimicrobial
activity of C4 always increased when compared to C3. These results suggest that although the
majority of the antimicrobial activity is highly dependent on amino acids 85-89, other regions of
the C terminus may make minor contributions to the full antimicrobial effect of CCL28.
To further determine if the C4-C5 region (amino acids 85–89) was essential to the
antimicrobial activity of CCL28, we next constructed a mutation in which this region was
deleted and amino acid 84 was followed by the amino acids corresponding to amino acids 90–
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Figure 2. The C-terminus of CCL28 is indispensable for efficient antimicrobial activity of this
chemokine. (A) SDS-PAGE (16%) of Ni-column purified recombinant protein. F, full length
protein. 1-9, serial C-terminus truncation mutant protein, as indicated in panel B. (B) Sequential
truncations (C1–C9) made to the CCL28 protein. The locations where the deletions were made
are indicated by arrows below the protein sequence. Names (C1–C9) and amino acid residue
numbers included in each protein are listed under each mutation. Antimicrobial activity of fulllength mCCL28, CCL5, and each CCL28 truncation mutant (C1–C9) was tested on S. aureus (C)
or P. aeruginosa (D). Antimicrobial activity of CCL28 following the deletion of amino acids 85–
89 (RKDRK) on S. aureus (E) and P. aeruginosa (F). Bacterial survival is displayed as CFU/mL.
Data shown are means ± SEM (n53) and are representative of four independent experiments.

27

108 of the wild-type protein. In these experiments, we observed a dramatic reduction in
antimicrobial activity when compared with the full-length CCL28 protein. However, although
the antimicrobial activity of this mutant protein greatly decreased following the specific deletion
of amino acids 85–89, antimicrobial activity was still detected in this mutant (Fig. 2D and E).
These results suggest that although the antimicrobial activity of CCL28 is highly dependent on
amino acids 85—89, other regions of the C-terminus may make minor contributions to the full
antimicrobial effect.

The antimicrobial activity of CCL28 is dependent on charged amino acids at the protein’s Cterminus
The C-terminus of CCL28 is rich in positively-charged amino acids. It has been
suggested that the recognition/killing process used by some AMP is mediated through
electrostatic interactions between positively-charged amino acids of the antimicrobial protein and
negatively-charged bacterial cell components (Huang 2000). It is clear from our results in figure
2 that a highly positively-charged region of CCL28, RKDRK, which spans amino acids 85-89 is
vital to the antimicrobial activity of the protein. Additionally, we hypothesized that other
positively-charged amino acids in the C-terminal region may contribute to the antimicrobial
killing observed in the full length protein. To evaluate the effect of specific, positively-charged
amino acids we constructed mutant proteins which contained amino acid substitutions. The
antimicrobial activity of these mutant proteins was then determined in standard antimicrobial
assays. Based on our hypothesis that positively-charged amino acids outside the 85-89 region
were important for full antimicrobial activity, we constructed amino acid replacement mutants in
which R108 (the terminal amino acid) was changed to a neutral alanine or negatively charged
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aspartate. In these experiments we observed that the insertion of an alanine in place of an
arginine resulted in a consistent decrease in the antimicrobial activity observed (p=0.056 and
0.014 for experiments using S. aureus and P. aeruginosa respectively). Furthermore, conversion
of R108 to a negatively-charged amino acid (aspartate) resulted in a statistically significant loss
of antimicrobial activity (p=0.038 and 0.027 for experiments using S. aureus and P.
aeruginosa respectively). As an additional control, we also converted a negatively-charged
amino acid (E105) to a positively-charged amino acid. This experiment resulted in antimicrobial
activity levels consistent with the full length CCL28 protein (Figure 3). These results suggest
that although the highly charged region of CCL28 included in the C4 truncation is essential to
the antimicrobial activity of CCL28, other positively-charged amino acids may also contribute to
the overall antimicrobial effect of the protein. This is illustrated by the significant change in the
antimicrobial activity of CCL28 following charge reversal of the terminal amino acid of the
CCL28 protein.

Highly charged amino acids in the C-terminal region of CCL28 are well conserved across
species.
The C-terminal region of CCL28 is highly-positively charged with cationic amino acids
constituting nearly 50% of the region. As shown in figure 2, truncation experiments
demonstrated that a single highly charged region (amino acids 85-89) was vital in mediating
antimicrobial activity. The first two amino acids in this region are well conserved with R or K
being found at this position in a wide variety of species. The amino acids in the next two
positions (87-88) are more variable, and are generally followed by a positively-charged amino
acid in position 89. These results suggest that the entire five amino acid region contained in
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Figure 3. Antimicrobial activity of CCL28 is reduced by charge reversal of the terminal amino
acid. (A) Location of amino acid substitutions in the CCL28 protein; the amino acids
manipulated by substitution are in bold and underlined. The one letter amino acid abbreviation,
following the numerical location, indicates the amino acid present in the mutant protein. (B)
Results of antimicrobial assays using mutated proteins tested on S. aureus. (C) Antimicrobial
assay results using P. aeruginosa. Surviving bacterial cells were quantitated as CFU/ml.
Antimicrobial activity of full length mCCL28, CCL5 and each CCL28 mutant. Data are shown
as the means ± SEM (n=3) and are representative of three independent experiments.

30

truncation 4 is not highly conserved among species, but that the first two positively-charged
amino acids of this region are well conserved among diverse species
Analysis of the CCL28 primary amino acid sequence of multiple species shows that the
overall consensus sequence for the 85-89 amino acid region is KRNSK with the human sequence
being RKNSN. It is clear that this region is essential to the activity of murine CCL28. However,
it is unclear if variations in this region between different species result in differences in the
antimicrobial activity of CCL28. It has previously been shown that murine CCL28 is slightly less
effective as an antimicrobial chemokine than human CCL28 is (Hieshima, Ohtani et al. 2003).
The divergence of murine CCL28 from the consensus and human sequences in this essential
region may contribute to the lower antimicrobial activity of mouse CCL28 compared to human
CCL28.
The chemokines CCL28 and CCL27 both bind the CCR10 chemokine receptor and
mediate migration of CCR10 expressing lymphocytes. As mentioned previously, CCL27 has not
been shown to possess antimicrobial properties. We next compared the C-terminal region of
these two CCR10 ligands to assess if there were significant differences in the number of
positively-charged amino acids. Amino acid sequence comparison demonstrated that whereas
positively-charged amino acids were found to be highly abundant in the C-terminal region of
CCL28, positively-charged amino acids comprised only ~12% of the C-terminal region of the
CCL27 (Fig. 4B). These results suggest that positively-charged regions of CCL28 may be
essential to the antimicrobial function of this chemokine and also differentiate this chemokine
from the other CCR10 ligand, CCL27.
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Figure 4. The highly-charged nature of the C-terminus of CCL28 is well conserved across
species. The C-terminal region of CCL28 is highly positively-charged with ~45% of all amino
acids in this region being arginine, histidine, or lysine. Sequence alignment was performed using
the alignment program ClustalW2. Charged amino acids are shaded and conserved cysteines are
underlined. The amino acids corresponding to the essential region RKDRK from each species are
boxed. (A) Sequence alignments of the C-terminus of CCL28 from sheep, cow, pig, dog, human,
chimpanzee, monkey, and mouse. (B) Sequence alignments of the C-terminus of murine CCL28
and CCL27.
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Both N and C regions are necessary for full antimicrobial activity of CCL28
Based on the above observation, we sought to determine if the C-terminal region of the
protein is an effective antimicrobial agent alone, or if optimal function requires the N-terminal
region of the chemokine. Additionally, we designed experiments to determine if activity of the
C-terminal region requires a specific CC chemokine backbone for optimal function. To address
these questions, we first generated two truncated proteins. The first consisted of the C-terminal
52 amino acids, and the second consisting of the 56 N-terminal amino acids of CCL28 (Fig. 4A).
These proteins were then used in microbial killing assays. Results of antimicrobial assays using
truncated proteins demonstrate that the C-terminal 52 amino acid peptide of CCL28 consistently
killed more bacteria than the N-terminal 56 amino acid peptide. Statistical analysis of the
antimicrobial activity of the C-terminal peptide compared to CCL5 killing resulted in P values of
0.063 and 0.031 for S. aureus and P. aeruginosa, respectively. Conversely, the P value of
experiments in which the antimicrobial activity of the N-terminal peptide was compared to
CCL5 resulted in P values that were clearly not significant (P= 0.185 and 0.141). These results
suggested that the C-terminus of the protein alone did exhibit some antimicrobial activity as has
been reported previously. However, the antimicrobial effect of the full length protein was clearly
far superior to the C-terminal 52 amino acids peptide (Figure 5A).
Based on results from figures 2 and 5B, which showed that amino acids in the C-terminus
were essential, but not sufficient, for full antimicrobial activity, we hypothesized that full
antimicrobial activity of CCL28 is dependent on the C-terminal region, in conjunction with an
appropriate N-terminal region. We next sought to determine if the activity of CCL28 was
dependent on a specific N-terminal region or if the N-terminal region of another chemokine
could be substituted for the N-terminal region of CCL28 and still retain the antimicrobial
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properties of the full length CCL28 protein. To perform these experiments, we constructed two
chimeric proteins. The first consisted of the N-terminal region of CCL27 fused to the C-terminal
region of CCL28. CCL27 is the most closely related chemokine to CCL28 and both CCL27 and
CCL28 bind the CCR10 chemokine receptor on lymphocytes. CCL27 has not been shown to
exhibit antimicrobial properties. The second chimeric protein constructed consisted of the Nterminal region of CCL5 fused to the C-terminus of CCL28. CCL5 binds the CCR1, CCR3 and
CCR5 chemokine receptors and has not been shown to possess antimicrobial properties. In
assays testing the killing activity of these chimeric proteins on S. aureus, full antimicrobial
activity was seen in the CCL27/CCL28 chimera, when compared to full length CCL28.
Additionally, full length CCL28 protein was significantly more effective in killing bacteria than
the CCL5/CCL28 chimera (p=0.014), (Fig. 4C). This was not surprising due to the high
homology of CCL28 and CCL27 and low homology of CCL28 and CCL5 at the N-terminal
region. In assays testing the killing activity of chimeric proteins on P. aeruginosa, full
antimicrobial activity was seen using both CCL27/CCL28 and CCL5/CCL28 chimeras (Fig. 5B).

The first two conserved cysteines of CCL28 are not required for antimicrobial activity
CC chemokines are so named due to the presence of a conserved CC sequence in the Nterminal region of the chemokine. Chemokine-mediated chemotaxis has been shown to be
dependent on these conserved cysteines and these cysteines are essential to appropriate
chemokine structure (Rajagopalan and Rajarathnam 2006; Prado, Suetomi et al. 2007). In an
effort to determine if the first two conserved cysteines of CCL28 are essential in the
antimicrobial activity of CCL28, a mutant protein was constructed in which an alanine was
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Figure 5. Antimicrobial assay of chimeric proteins. CCL27N-CCL28C, CCL5N-CCL28C, Cterminus only, and N-terminus only were used against S. aureus (A) and P. aeruginosa (B). The
decision of N and C terminus are based on the alignment as shown in figure 2. Mutants are
indicated (X-axis) and surviving bacterial cells were quantitated as CFU/ml (Y-axis). Their
activities were compared with recombinant full length CCL28 and CCL5. Each mutant assay was
triplicated. Data shown are means ± SEM.
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Figure 6. The first two conserved cysteines are not important for antimicrobial activity. Amino
acids that have been deleted in the sequence are in boxes (A). S. aureus (B), P. aeruginosa (C),
were exposed to the deletion and substitution mutant peptides, and surviving bacterial cells were
quantitated as CFU/ml. Their activities were compared with recombinant full length CCL28 and
CCL5. Each mutant assay was triplicated. Data shown are means ± SEM.
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substituted for the two cysteines at positions 8 and 9 of the mature protein. In employing these
mutant proteins in our antimicrobial assays, we observed no decrease in the antimicrobial
activity of the mutated CCL28 protein (Fig. 6). These data suggest that these highly conserved
cysteines are not required for the antimicrobial activity of CCL28.

Discussion

Innate immunity is thought to be an ancient immune stratagem preceding the evolution of
adaptive immunity. Antimicrobial peptides function as a key component of the innate immune
system and have been identified in organisms as diverse as humans and plants (Zasloff 2002). A
wide variety of antimicrobial proteins have been identified including histatins, defensins, and
more recently some chemokines. Expression of the antimicrobial chemokine CCL28 has been
shown to be upregulated following epithelial inflammation (Eksteen, Miles et al. 2006; Hansson,
Hermansson et al. 2008). Additionally, this chemokine has been shown to be constitutively
expressed and highly concentrated in mucosal secretions such as milk and saliva (Hieshima,
Ohtani et al. 2003). The localization of this antimicrobial chemokine in mucosal secretions may
provide constitutive innate immune defense against a variety of bacterial pathogens.
The function of chemokines as antimicrobial proteins represents an elegant aspect of
immuno-efficiency. Antimicrobial chemokines function both to recruit leukocytes to specific
tissues as well as to protect these surfaces through direct antimicrobial activity. Dual
functionality of some defensins has also been demonstrated, in which these peptides have been
shown to be chemotactic, as well as antimicrobial, suggesting evolutionary pressures have long
linked these two seemingly distinct biological functions (Chertov, Michiel et al. 1996; Yang,
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Chertov et al. 1999). A potential evolutionary advantage of the inclusion of antimicrobial
properties with chemokines, as opposed to histatins and defensins, is that chemokines efficiently
bind heparin sulfate moieties, commonly found on the surface of epithelial cells (Lortat-Jacob,
Grosdidier et al. 2002; Lau, Paavola et al. 2004; Handel, Johnson et al. 2005). The binding of
chemokines to epithelial surfaces has been proposed to increase the effective concentration of
CCL28 at mucosal surfaces (Hieshima, Ohtani et al. 2003).
In this study we sought to determine which regions of the CCL28 protein are essential to
antimicrobial activity and if positively-charged amino acids play a role in the microbicidal
properties of CCL28. Our findings strongly support a vital role for amino acids 85-89 of CCL28,
as deletion of this region resulted in a dramatic reduction in the antimicrobial activity of CCL28.
Having a positively-charged amino acid in one of the first two positions of this sequence (K or R)
is a trait strongly conserved in species ranging from rodents to primates and ruminants. In
addition to this single indispensable region, charge neutralization and reversal experiments on
the C-terminal amino acid of murine CCL28 suggest that other positively-charged amino acids in
the C-terminus contribute to the antimicrobial activity of the protein. The hypothesis that
positively-charged amino acids contribute to the antimicrobial properties of CCL28 is supported
by sequence comparison of CCL27 and CCL28. Each of these chemokines binds the CCR10
chemokine receptor and efficiently mediates the directed migration of CCR10 expressing
lymphocytes. However, the non-antimicrobial CCL27 contains relatively few positively-charged
amino acids when compared to CCL28. The characteristic of C-terminal positively-charged
amino acids in CCL28 is broadly conserved across species; suggesting that, evolutionary
pressures have continued to select for a positively-charged antimicrobial C-terminal region since
the divergence of human and mouse 65-85 million years ago.

38

In addition to investigating or exploring the necessity of the highly positively-charged Cterminal region of CCL28, we investigated if disulfide bonding within CCL28 was important for
the observed antimicrobial function of the protein. Antimicrobial chemokines are generally
larger and more structurally complex than other antimicrobial peptides. CC chemokines have a
conserved structure throughout the N-terminus, with three anti-parallel β-sheets followed by a Cterminal α-helix (Allen, Crown et al. 2007). The α-helix of CC chemokines has been postulated
to serve as a structural scaffold, and this region has been switched between chemokines without
loss of chemotactic specificity (Rajagopalan and Rajarathnam 2006). The N-terminus of CC
chemokines and the accompanying structural complexity has been demonstrated to be important
for chemokine receptor binding and activation of leukocytes (Ott, Lio et al. 2004; Prado,
Suetomi et al. 2007). Previous reports have not investigated the role of proper protein folding on
the antimicrobial activity of CCL28. Replacement of the canonical consecutive cysteines is
predicted to destroy disulfide bonding within the chemokine, which in turn should significantly
alter the tertiary structure of the protein. Mutating these cysteines in other chemokines has
resulted in a loss of receptor binding and cellular activation. In these experiments we observed
no decrease in antimicrobial activity of CCL28. These results suggest that if the tertiary structure
of CCL28 is important in mediating its antimicrobial activity, this structure is formed
independently of the disulfide bonding known to be vital for chemokine receptor binding.
Disulfide bonding has also been shown to be essential for the chemotactic activity of other AMP
but not for the antimicrobial activity of those AMP (Rajarathnam, Sykes et al. 1999; Wu, Hoover
et al. 2003; Kluver, Schulz-Maronde et al. 2005; Ramamoorthy, Thennarasu et al. 2006).
Although the disulfide bonding of CCL28 does not appear essential for efficient antimicrobial
activity, it is likely that an ordered tertiary structure of CCL28 is essential for antimicrobial
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function. In other AMPs, it has been demonstrated that essential, three-dimensional structures are
formed following interaction with a bacterial membrane (Schibli, Hunter et al. 2002; Mani, Cady
et al. 2006; Campagna, Saint et al. 2007; Lourenzoni, Namba et al. 2007).
Antimicrobial assays using chimeric chemokines demonstrated that the N-terminus of
CCL27 fused with the C-terminus of CCL28 resulted in full antimicrobial activity against P.
aeruginosa and S. aureus. However, the chimeric protein composed of the N-terminus of CCL5
fused with the C-terminal region of CCL28, resulted in full strength antimicrobial activity
against P. aeruginosa, but only partial killing of S. aureus. These results suggest the possibility
that there are different structural requirements for the killing of Gram-positive and Gramnegative bacteria, and these requirements may involve appropriate interactions between the Nterminus and the C-terminus of the chemokine. It appears that efficient killing of P.
aeruginosa requires the interaction of the C-terminus of CCL28 with the N-terminus of a CC
chemokine (CCL5 or CCL27). Conversely, the killing of S. aureus is dependent on the
interaction of the C-terminus of CCL28 with the highly conserved N-terminal region of CCL27.
The observed results, in the ability of these chimeric chemokines to kill Staphylococcus and
Pseudomonas, are clearly not due to the N-terminal region alone, as similar antimicrobial
activities were seen (compared to BSA control) in both types of bacteria when using the CCL28
N-terminal peptide in antimicrobial assays. Conversely, the C-terminal peptide alone shows
higher efficacy in killing Pseudomonas than Staphylococcus bacteria. These results suggest Cterminal region interactions with the N-terminal region of the protein are less important for
efficient antimicrobial activity of CCL28 against Pseudomonas than Staphylococcus bacteria.
The specific requirements for efficient interaction of the N-terminal region of the CCL27 and
CCL28 proteins that contribute to the killing of Staphylococcus remain enigmatic. However, in
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preliminary analyses, we have found that the hydrophobicity plots of the N-region of CCL27 and
CCL28 are highly similar. Conversely, hydrophobicity analysis of the N-region of CCL5 shows
that this region is distinctly different from CCL27 and CCL28 (data not shown). The distinct
hydrophobicity profile seen in these proteins may contribute to an amphipathic structure
necessary for CCL28 lethality against Staphylococcus, but not Pseudomonas bacteria.
The potential for antimicrobial proteins interacting with Gram-positive and Gramnegative bacteria via slightly different mechanisms is also supported by experiments in which we
compared in-house prepared CCL28 to commercial CCL28. In these experiments
Staphylococcus and Pseudomonas bacteria were used to compare the antimicrobial activity of inhouse prepared CCL28 to the antimicrobial activity of commercially obtained CCL28. Results
indicated that when using S. aureus in these assays, there was no difference between commercial
and in-house preparations of CCL28. However, in assays using P. aeruginosa, in-house CCL28
consistently resulted in greater levels of CCL28 antimicrobial activity. This may be due to
residual his-tag remaining on in-house prepared CCL28 interacting preferentially with the Gramnegative cell wall and increasing the antimicrobial activity of this recombinant protein.
In conclusion, data presented here demonstrate that positively-charged amino acids in the
C-terminus of CCL28 play a key role in the antimicrobial activity of this dual-function
chemokine. This observed antimicrobial activity is not dependent on the presence of the
characteristic paired cysteines for which CC chemokines are named. Our data also demonstrate
that the C-terminal region of CCL28 is necessary but not sufficient for full antimicrobial activity.
Full antimicrobial activity is observed when the C-terminal region of CCL28 is combined with
an appropriate N-terminal region of a non-antimicrobial chemokine.
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Chapter 3: CCL28 binds to bacteria in vivo

Abstract

Most chemokines have been found to have antimicrobial activity in vitro. It has been
hypothesized that the decrease in killing activity at high salt concentration is a result of dissolved
ions adversely affecting the charge-mediated binding between chemokine and bacteria. Here we
demonstrate using the mucosal-expressed antimicrobial chemokine CCL28 and Salmonella
typhimurium bacteria, that CCL28 binds bacteria at both high and low salt concentrations.
However, more CCL28 binding per bacterium occurs in low salt conditions. This finding
suggests that CCL28’s inability to bind bacteria in high salt conditions does contribute its lower
killing activity. We also demonstrate that endogenously-expressed CCL28 binds to commensal
bacteria in the mouse large intestine. This is the first research demonstrating a direct interaction
between CCL28 and bacteria in vivo.

Introduction

Chemokines are a group of small proteins that play essential roles in leukocyte migration
and accumulation. In addition to their well-studied roles in mediating the directional migration
of leukocytes via interactions with cognate receptors, these proteins also play key roles in a
number of other biological processes such as angiogenesis, cancer biology, hematopoiesis, and
direct antimicrobial activity against microbes (Esche, Stellato et al. 2005; Pivarcsi, Muller et al.
2007; Keeley, Mehrad et al. 2010; Struyf, Salogni et al. 2010). The pleiotropic nature of
chemokines in such essential processes illustrates the importance of a better understanding of all
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aspects of chemokine biology, and one such task is to understand the antimicrobial role of
chemokines in innate immunity.
Antimicrobial chemokines share many traits with conventional antimicrobial proteins
such as defensins, cathelicidin, and histatins. For example, they are all cationic and are thought
to bind to the anionic microbial membrane, ultimately causing permeabilization or disruption of
the microbial membrane (Hieshima, Ohtani et al. 2003; Brogden 2005; Lee, Hung et al. 2008;
Linge, Collin et al. 2008). Like defensins, antimicrobial chemokines show reduced activity in
physiological (150 mm) salt concentrations (Hieshima, Ohtani et al. 2003; Starner, Barker et al.
2003; Yang, Chen et al. 2003; Linge, Collin et al. 2008; Maerki, Meuter et al. 2009). Why these
proteins function optimally in low salt solutions is unclear, but, it has been hypothesized that the
large number of charged ions in high salt solutions essentially shields the negatively-charged
membrane from the positively charged AMP, resulting in a failure to recognize and bind the
bacterial membrane (Selsted and Ouellette 2005). However, this hypothesis has not been
thoroughly tested.
The chemokine CCL28 is known to play an essential role in mediating the migration and
accumulation of IgA antibody secreting B cells (IgA ASCs) to a variety of mucosal tissues
(Hieshima, Kawasaki et al. 2004; Wilson and Butcher 2004). This migration is mediated by
interactions with the CCR10 chemokine receptor that is predominantly found on IgA ASCs as
well as some T cells (Wang, Soto et al. 2000). CCL28 is expressed by mucosal epithelial cells
and is found in high concentrations in saliva and breast milk (Hieshima, Ohtani et al. 2003).
CCL28 mRNA is also highly expressed in a variety of exocrine glands as well as in the large
intestine (Nakayama, Hieshima et al. 2003). CCL28 has been shown to kill microbes only in low
salt buffers and not in what is commonly considered “physiologically normal” conditions
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(Hieshima, Ohtani et al. 2003). However, what constitutes as “physiologically normal” is clearly
dependent on what part the body is being sampled. Many mucosal tissues are surrounded by low
salt environments. For example milk and the intestinal lumen, both sites of high CCL28
expression, have considerably lower salinity than blood. Although, CCL28 is highly expressed at
mucosal surfaces and efficiently kills bacteria in low salt solutions, it is unclear if this saltsensitive killing is due to decreased binding of the chemokine or decreased activity of the
chemokine once bound. Furthermore, although CCL28 is known to be expressed in many
mucosal tissues it has not previously been demonstrated if this chemokine interacts with bacteria
in vivo.
In this study we addressed the questions of how buffer salinity affects the interaction
between CCL28 and bacteria. Furthermore we sought to determine if CCL28 protein interacts
with bacteria in vivo. Using in vitro binding and killing assays we demonstrate that CCL28 kills
Salmonella typhimurium at both 20 mM and 150 mM NaCl solutions, but much more efficiently
in 20 mM conditions. Using a flow cytometry based assay to determine chemokine/bacteria
binding, we demonstrated that chemokine binding occurs in both high salt (150 mM) solutions as
well as in low salt (20 mM) solutions. Although the percent of bacteria bound by chemokine
was identical in the two salt solutions, the intensity of chemokine binding to individual bacteria
in the two salt solutions appears to vary, with more CCL28 molecules binding each bacterium in
20 mM salt solution compared to the 150 mM solution. Lastly we demonstrate that
endogenously produced CCL28 binds normal flora bacteria in vivo. These results demonstrate
that CCL28 protein is expressed in the lumen of the murine intestinal tract and that within this
physiological environment this chemokine efficiently binds to bacteria.
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Materials and Methods

Mice and bacteria
Two week old neonatal mice were used for this study. All mouse studies were performed
according to Brigham Young University guidelines for animal use and care. Wide type (LT2,
ATCC 15277) and phoP mutant Salmonella typhimurium (strain TT16826, stv(LT2)
phoP::Tn10$COM rough) were kindly provided by Dr. Julianne Grose (originally from Dr. John
Roth, UC Davis). All bacteria were grown in Luria broth (LB) at 37°C with vigorous shaking.
Salmonella typhimurium containing the pAKgfp1 plasmid (kindly provided by Dr. David
Erickson, originally from Addgene, 14076), which constitutively expresses green fluorescent
protein were grown in LB medium supplemented with 100 µg/ml of ampicillin.

Killing assay
Subcultures of S. typhimurium (wild type and phoP mutant) were grown to an OD600 of
0.6. Bacteria were suspended in 20 mM or 150 mM NaCl supplemented with 10 mM Tris-HCl
pH 8.0. Bacteria were then diluted approximately 2000 times to achieve a concentration of
~10,000 bacteria/50ul buffer. Bacteria were diluted in 20 mM or 150 mM solutions containing 0
ng/ µl, 2.5 ng/ µl, 5 ng/ µl, 10 ng/ µl, or 20 ng/ µl, final concentration of CCL28 (Peprotech).
Bacteria/chemokine solutions were then incubated for 30 min at 37°C with shaking. Following
incubation, the samples were spread on to tryptic soy agar plates. After incubating the plates at
37°C for 12- 20 hrs, bacterial colonies were counted. The percent killing of each solution was
determined by using the number of surviving bacteria in the no chemokine control as 100%
survival. The number of bacteria that grew in the CCL28 containing assays was divided by the

45

number of bacteria that grew in the control assays to determine percent survival in different
concentrations of NaCl and CCL28.

Flow cytometry
S. typhimurium bacteria were subcultured, from an overnight culture, in TSB medium
until an OD600 of 0.6 was achieved (~3hours). 100 µl of these this subculture was diluted in 1 ml
of 20 mM or 150 mM NaCl solution and then washed by centrifuging the solution (2900Xg) for
5 minutes. The bacteria-containing pellet was then resuspended in 100 µl of the appropriate NaCl
solution. Bacteria were then combined with 0.5 µg of recombinant CCL28 (Peprotech) and
incubated on ice for 30 minutes. Following this incubation, the cells were washed with ice cold
wash buffer consisting of PBS supplemented with 0.5% BSA (Sigma). Following washing, the
bacteria were incubated with 1 µg polyclonal biotin labeled anti-CCL28 antibody (R&D Systems,
Minneapolis, MN) diluted in wash buffer, for 30 minutes on ice. Cells were then washed and
incubated with APC labeled streptavidin conjugate (Becton Dickinson) for 30 minutes followed
by a final wash. Stained bacteria were then visualized using flow cytometry. Negative controls
consisted of bacteria alone and bacteria incubated with secondary antibody/APC conjugate in the
absence of primary antibody.

In vivo binding of chemokine to bacteria
Purification of intestinal bacteria was performed as described previously (Kotarsky,
Sitnik et al. 2010). 2~3 week old mice had their cecums and large intestines removed. Intestines
were then cut longitudinally and the contents were dispensed into 2ml cold PBS. For baby mice
stomach bacteria purification, the stomach was cut open and minced and dissolved in PBS. The
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solution was vortexed vigorously for 1 minute and allowed to sediment for another 2 minutes on
ice. 1.5 ml of supernatant was then transferred into a 1.7 ml microcentrifuge tube. The solution
was spun at maximum speed for 10 seconds in a microcentrifuge tube. The supernatant was then
discarded and the bacteria-containing pellet was resuspended in 1 ml cold PBS. The resuspended
pellet was centrifuged at 200×g for 3 minutes and this process was repeated twice. Lastly, the
clear supernatant was centrifuged at maximum speed for 10 seconds and the pellet was
resuspended in 50 µl of PBS. The purified bacteria were subjected to flow cytometry analysis.

Results

Several types of bacteria are to be susceptible to CCL28-mediated killing in low salt
solutions. However, no previous research has tested susceptibility of Salmonella to CCL28mediated killing. We first sought to determine if Salmonella was susceptible to CCL28mediated cell death and to confirm the salt-sensitive nature of this killing. To do this, first, we
incubated wild type Salmonella with varying concentrations of CCL28 in 20 mM NaCl or 150
mM NaCl and the percent of surviving bacteria was determined as described in Materials and
Methods. We observed a statistically significant difference in bacterial death at 20 mM and 150
mM NaCl at most chemokine concentrations tested. Importantly, although bacterial killing was
more efficient at 20mM concentrations, significant killing was also seen at 150mM salt
concentrations (Figure 1A). Salmonella deficient in the phoP gene were previously shown to be
highly susceptible to killing by a variety of antimicrobial peptides. However, no previous studies
have tested the susceptibility of these mutant bacteria to chemokine mediated cell death, so we
next tested the susceptibility of the Salmonella phoP mutants to CCL28-mediated cell death. As
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shown in figure 1B phoP mutant Salmonella were highly sensitive to the chemokine CCL28 at
low salt concentrations. At high salt concentrations (150mM NaCl), there were also substantial
levels of bacterial cell death at chemokine concentrations of 5ng /µl and above. These studies
demonstrate that the phoP mutation renders bacteria highly sensitive to CCL28-mediated killing.
Furthermore, although this killing occurs optimally in low salt solutions, killing also occurs at
statistically significant levels at high salt concentrations.
Recognition and binding of the bacterial membrane by antimicrobial proteins is an
essential first step in effecting bacterial death. We next sought to determine if and to what extent
binding of bacteria by CCL28 is influenced by the salt concentration of the solution. As phoP
mutant Salmonella were shown to be highly sensitive to CCL28 mediated cell death we utilized
this strain of bacteria in our subsequent assays. To detect the amount of CCL28 binding to
individual bacteria we used a methods similar to that described by Kotarsky et al (Kotarsky,
Sitnik et al. 2010). Chemokine binding to bacteria was visualized using flow cytometry as
described in Materials and Methods. Flow cytometric analysis allowed the simultaneous
determination of both the percentage of bacterial cells bound by chemokine, in varying salt
concentrations, as well as the determination of the relative amount of chemokine bound to
individual bacteria. As demonstrated in figure 2 A-C a similar percentage of bacterial cells was
bound by chemokine in experiments using both 20 mM NaCl and 150 mM NaCl. However, it
was also observed that the fluorescence intensity of staining was much higher for the cells
stained in 20 mM NaCl than those in 150 mM NaCl. Through averaging the results from 5
independent experiments, it was observed that the intensity of staining on cells bound to
chemokine in 20 mM NaCl was ~2.5 times brighter than those cells stained in 150 mM NaCl.
These results combined with those in figure 1 demonstrate that the antimicrobial chemokine
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CCL28 readily binds bacteria in both high and low salt solutions. However, this interaction and
bacteria cell death occurs more efficiently in low salt (20 mM) conditions. These results
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Figure 1. CCL28 kills Salmonella typhimurium efficiently in 20 mM NaCl concentrations. The
antimicrobial activity of CCL28 in 20 mM and 150 mM NaCl solutions was determined using
varying levels of the chemokine as listed on the X-axis. Bacterial survival is plotted on the Yaxis and was determined by performing plate count viability assays and comparing them to the
number of bacterial colonies from assays in which no chemokine was added. (A) Results of
assays using wild type S. typhimurium bacteria. (B) Results of assays using a phoP mutant of S.
typhimurium. Data shown are means + SEM. Graphs are generated from three independent
experiments. Statistical differences between percent survival of bacteria in 20 mM and 150 mm
NaCl are shown; * indicates p<0.05, ** indicates p<0.01.
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demonstrate a direct correlation between the binding of chemokine to bacteria and the
subsequent cell death of bacteria.
CCL28 mRNA is highly expressed at several mucosal sites with particularly high
expression levels observed in the large intestine. The large intestine is constitutively colonized
by large numbers of bacteria and preventing tissue damage caused by these bacteria is essential.
Based on this fact, we next sought to determine if endogenously expressed CCL28 is expressed
at high enough levels in this mucosal tissue to efficiently bind to commensal bacteria in vivo. In
these experiments we collected intestinal contents from two-week-old mice. Using neonatal
mice provided a model in which experimental animals were consuming CCL28 through the milk
as well as producing it in their large intestines. In these experiments, bacteria were collected
from the mice and purified as described in Materials and Methods. Bacteria were stained directly
with anti-CCL28 antibodies in an effort to detect endogenously bound chemokine using flow
cytometry. Controls consisted of staining cells with anti-CCL17 antibodies, since CCL17 has
not been shown to be expressed in the intestinal tract. Results showed that greater than 50% of
bacterial cells isolated from the large intestine were bound to CCL28 (Figure 3). These results
are the first to demonstrate the direct interaction between commensal bacteria and CCL28 in vivo.

Discussion

The use of antimicrobial proteins to protect organisms from microbial attack is an ancient
stratagem utilized by a broad array of organisms ranging from plants to humans, with over 1000
AMPs described to date (De Smet and Contreras 2005). Despite the vast numbers of organisms
which utilize AMPs and the large number of AMPs identified, surprisingly little is known about
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Figure 2. CCL28 efficiently binds S. typhimurium in vitro. The ability of CCL28 to interact with
and bind to bacteria in high and low salt concentrations was determined using flow cytometry.
(A & B) Representative histograms of bacterial cells bound by CCL28 in 150 mM and 20 mM
NaCl concentrations respectively. Markers indicating positive and negative staining cells were
set using negative controls. The Y-axis represents the cell count of S. typhimurium. The X-axis
represents the intensity of CCL28 binding to individual bacteria. (C). Percent of bacteria bound
by CCL28. Data shown are means + SEM. (D) Median fluorescence intensity of bacteria
following staining with CCL28 (Y-axis) in 20 mM and 150 mM NaCl solutions (X-axis). *
Indicates that differences between median fluorescence staining in 20 mM and 150 mM are
statistically significant p<0.05. Panel C and panel D represent the combined results of 5
independent experiments.
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Figure 3. Endogenous CCL28 binds to commensal bacteria in vivo. (A & B) Representative
histograms showing the percent of bacteria binding to CCL28 in vivo was measured through the
addition of anti-CCL28 antibody to bacteria collected from the mouse large intestines. Negative
controls consisted of treating bacteria with anti-CCL17 antibody. Y-axis indicates the number of
bacteria. X-axis indicates the fluorescence intensity of individual bacteria. (C) Combined
results from 5 mice. Y-axis represents percent of bacteria stained by the antibody indicated in
the X-axis. Data shown are means + SEM. ** indicates statistically significant differences
p<0.01.
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the actual antimicrobial role of these proteins in vivo. Antimicrobial chemokines constitute a
recently described subgroup of dual function AMPs, which means they have antimicrobial
characteristics and are also involved in cell chemotaxis and migration (Esche, Stellato et al.
2005). Cationic AMPs, including antimicrobial chemokines, appear to kill microbes in a saltsensitive manner (Hieshima, Ohtani et al. 2003; Yang, Chen et al. 2003; Linge, Collin et al.
2008). The in vivo antimicrobial role of antimicrobial chemokines remains severely understudied.
Previous research has clearly shown that CCL28-mediated bacterial cell death occurs
optimally at low salt concentrations (Hieshima, Ohtani et al. 2003). It has been proposed that
cationic AMPs are more able to bind bacteria through electrostatic interactions in the absence of
excess free ions (Zasloff 2002). However, previous research has not quantified how the binding
of chemokines to bacteria is influenced by environmental salt concentrations. Here, we
demonstrate by flow cytometry that CCL28 efficiently binds bacteria in both 20mM and 150mM
salt concentrations. Although equivalent percentages of bacteria were found to bind CCL28 in
both salt concentrations, CCL28 binding per bacterium was significantly enhanced in low ionic
strength conditions. Previous research by Linge et al has shown that human CXCL6 binding to S.
aureus is totally abrogated in 150 mM NaCl (Linge, Collin et al. 2008). This discrepancy could
be a result of the bacteria used in our assays or the binding of CXCL6 could be fundamentally
different than that of CCL28. The Gram-negative bacteria S. typhimurium phoP strain used in our
assays is efficiently killed by CCL28 even at 150 mM NaCl solutions. Our results clearly
demonstrate that CCL28 binds bacteria more efficiently at low salt concentrations.
Enhanced CCL28 binding in low salt solutions may be a result of the bacteria swelling
under the osmotic stress of the low salt solution which may then expose more chemokine binding
sites on each bacterium. The swelling of bacteria under low osmotic conditions may also
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accelerate bacterial membrane rupture and cell death. Alternatively, it is possible that increased
numbers of positively and negatively charged ions in high salt buffers interfere with the
electrostatic attraction of chemokines to their targets as previously hypothesized. This data
suggests that although CCL28 binding to bacteria occurs over a broad range of salt
concentrations efficient bacterial cell death occurs preferentially once a threshold of CCL28
binding has been achieved.
It has been hypothesized that physiologically normal salt concentrations (150mM) will
decrease efficient chemokine killing in the blood stream because chemokines will not be able to
bind to bacteria efficiently. This is supported by our results and the results from Linge et al
(Linge, Collin et al. 2008). Such findings may cast doubt on the physiological relevance of such
salt sensitive proteins in the blood stream. However, the use of gene deficient animals has
shown in vitro that the killing of some defensins is salt-sensitive using in vivo assays. It is clear
that these proteins play an essential role in protecting the host from microbial challenge (Wilson,
Ouellette et al. 1999; Morrison, Kilanowski et al. 2002; Salzman, Ghosh et al. 2003; Chromek,
Slamova et al. 2006). These observations could be a result of these proteins being active only in
low salt microenvironments within the body. Conversely, these results could reflect low levels of
binding under in vivo conditions which, when combined with other components of the innate
immune system, may play a significant role in the clearance of invading microbes. It is clear
from the high levels of CCL28 binding observed in the murine large intestine that appropriate
conditions exist in this tissue to support high levels CCL28 binding to a large population of
commensal bacteria. Similar results have been observed for small intestine commensal bacteria
(data not shown). These results are the first evidence that endogenously produced CCL28 binds
to bacteria in vivo. However, it is still unclear how much chemokine must bind bacteria to effect
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CCL28-mediated bacterial cell death in vivo, and whether this threshold is reached under normal
in vivo conditions in the murine colon. It is likely that the in vivo activity of CCL28, and many
other antimicrobial peptides, does not solely depend not on a single protein but rather on the
combined effects of various components of the innate immune system working in concert.
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Chapter 4: Exploring CCL28 in vivo antimicrobial activity through the generating of a
CCL28 knockout mouse model

Introduction

Since identification of their antimicrobial activity, it has been proposed that some
mucosally expressed antimicrobial chemokines play a role in direct innate immune defense. This
proposal was made based on indirect research experiments. For example, some antimicrobial
chemokines are highly expressed on mucosal tissues and this expression can be further increased
after contact with bacteria or their components, such as CCL6, CXCL9, CCL20 (Hieshima,
Ohtani et al. 2003; Starner, Barker et al. 2003; Egesten, Eliasson et al. 2007; Maerki, Meuter et
al. 2009; Kotarsky, Sitnik et al. 2010). More supporting evidences came from studies in which
neutralizing antibody was administered to pulmonary expressed chemokines, such as CXCL9,
CXCL10, and CXCL11 (Crawford, Burdick et al. 2010). However, the in vivo antimicrobial
function of most of the antimicrobial chemokines in innate immune protection still remains
unclear.
Definitive evidence is necessary to understand the in vivo antimicrobial role played by
chemokines. The direct in vivo antimicrobial function of mouse α-defensin, β-defensin-1, human
β-defensin-5, and LL-37 has been demonstrated using knockout/in mouse models (Wilson,
Ouellette et al. 1999; Morrison, Kilanowski et al. 2002; Salzman, Ghosh et al. 2003; Chromek,
Slamova et al. 2006). Since mouse gene knockout techniques are not as formidable as before,
establishing a CCL28 knock-out mouse model may be a good way to demonstrate its
antimicrobial role in vivo.
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CCL28 is a good antimicrobial chemokine to use for demonstrating chemokine
antimicrobial function in vivo by a knockout mouse model. Namely, CCL28 is highly expressed
in a variety of mucosal tissues. Mucosal tissues are constantly challenged by different microbes.
If CCL28 plays a role in defending against microbial invasion in vivo, it may be effectively
demonstrated through a knockout mouse model. However, like most other chemokines, CCL28
is bi-functional. A simple CCL28knockout mouse model would be both deficient in CCL28
chemotactic and antimicrobial function. The ability of CCL28 to attract B cells and T cells is
important in the host’s ability to defend against microbial invasion. A simple knockout will not
work in this case. However, there is another chemokine, CCL27 that uses the same chemokine
receptor as CCL28 (CCR10), and according to previous research is not antimicrobial. Therefore
driving CCL27 expression under the control of the CCL28 promoter should provide efficient
recruitment of CCR10 bearing cells yet not provide any direct antimicrobial activity at mucosal
sites.
If successfully generated, a mouse model could be used to evaluate the antimicrobial
activity of CCL28 on the bacteria burden and mouse mortality following challenge with
pathogenic or on commensal bacterial. I have worked extensively to generate such a mouse
model. Although successful generation of transgenic mice has not yet been achieved, I have
successfully constructed targeting vectors and ES cell lines. The following section will
document my approach and methods.

Material and Method
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Targeting vector construction
A CCL28 targeting vector was constructed using a recombineering (recombinationmediated genetic engineering) method according to the paper published by Wu et al (2008). In
this method, a low copy number plasmid (pKD46) encoding lambda phage Red-recombination
proteins alpha, beta, and gamma mediates the homologous recombination in E. coli. In this
system, a short homologous arm (~50bp) is enough for high efficiency recombination.
The BAC clone (WI1-1632B20) containing the whole genomic DNA sequence for
CCL28 was ordered from BACPAC Resource Center. The CCL28 genomic sequence has 3
exons; the first one encodes for the signal peptide. The strategy utilized in this work was to
replace the second exon of CCL28 with the coding sequence of CCL27, as shown in the
following figure.

1

2

3

CCL27 CDS
Figure 1. Strategy to make a gene swap between exon 2 of the CCL28 gene and the CCL27
coding sequencing without the signal sequence but with a stop code.

Vector construction was performed as described in detail by Wu et al (2008). A brief
description of the methods used is described below.

Capturing the CCL28 gene from its BAC vector
A homologous arm was added to each end of the linear plasmid pSTART-K by PCR and
the linear plasmid was then used to capture the ccl28 gene by homologous recombination.
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Figure 2. The homologous recombination between the ccl28 gene and the plasmid. This will
result in the insertion of the ccl28 gene into the plasmid. This picture was modified from Wu, et
al., 2008.

The upstream and downstream primers are,
Bac-F forward:
GGTGAAAATGAATGGTTTAGAGTGGATGAGGGCAGTGTCAAGATTCTATTCGACTG
AATTGGTTCCTTTAAAGC
Bac-R reverse:
TGCACTGTGAGGGTGAACTGGTTTTGTTGGATGAAGTTTAAACATGGAAGGCCGCAC
TCGAGATATCTAGACCCA
Capture of the gene was confirmed by sequencing the recombination junctions through
the use of the following sequencing primers,
Pst-B-R5 reverse: CCAAGCAACTCTCCATCATGACACG
Pst-B-F5 forward: GTTAGTTCCCACTATGCATAAGGGC
PCR conditions were set as follows: 1µl of 10µM of each of forward and reverse primer,
1 µl of 50 ng/µl pStart-K plasmid, 2 µl of dNTP (2.5µM each), 2.5 µl PLATINUM pfx50 DNA
polymerase buffer and 0.5 µl polymerase (Invitrogen) in a total volume of 25 µl. PCR product
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was then gel purified. Competent BAC strain was transformed with plasmid pKD46, which
encodes for the recombinase. The pKD46 positive BAC strain was electroporated with 500 ng of
the above purified PCR product. Colonies grown on kanamycin selection plates were picked up
and then were grown in LB medium for plasmid extraction. Plasmid DNA samples were run on
agarose gel and those of the right size were chosen for sequencing to further confirm that they
were from the desired homologous recombination.

Generation of CCL27-chloramphenicol fusion gene for replacement into the CCL28 exon 2 by
homologous recombination
First, the chloramphenicol gene was amplified by PCR. An AscI restriction site was
added to each end and a homologous arm was added to the C-terminus of the chloramphenicol
gene through use of the following primers.
Cat F:
CTCAAACCCCCAACAGCAAAACTAATAGGGCGCGCCCACTTAACGGCTGACATGGG
AATTA
Cat R:
GGGGATAATCCGCATTCGGTTTCCCATGTCCTTGCTGAGGGACACTCACATGGCGCG
CCAGCATTACACGTCTTGAGCGATTGT
Second, the ccl27 gene was amplified by PCR. A homologous arm was added to the Nterminus of ccl27 through the use of following primers:
CCL27 F:
AGGCTGGTACTCTGCGGACGGTAATGCAAGCTCTCCCCTTTCTTGTAGCCTTGCCTCT
GCCCTCCAGCACTAGCTGCTGT
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CCL27 R:
TAATTCCCATGTCAGCCGTTAAGTGGGCGCGCCCTATTAGTTTTGCTGTTGGGGGTTT
GAG
Third, CCL27 F and Cat R primers were used to make the fusion gene of ccl27 chloramphenicol.
Finally, the fusion gene was then used to replace exon 2 of the ccl28 gene by homologous
recombination. Successful recombination colonies were selected on chloramphenicol selection
plates. Four colonies were picked and grown. Plasmids were extracted from those colonies and
the junctions were sequenced to confirm that the right recombination events had occurred.

Figure 3. The homologous recombination for replacement of exon 2 by ccl27- chloramphenicol
fusion gene. The plasmid pStart-k carrying ccl28 gene was generated from a previous step. The
chloramphenicol gene has an AscI site on each end, which will be used for the next step. This
picture was modified from Wu, et al., 2008.
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Insertion of positive selection marker---Ligate GFP-LoxP-Cre-Neo cassette with CCL27-pStartK plasmid
A positive selection marker is required to screen out the ES cells which have the target
vector recombined. Neomycin is used as the positive selection marker. For convenience, the
plasmid pEGFPpA-ACN containing EGFP-loxp-Ace-Cre-Neo-loxP was used. The plasmid was
digested by AscI and ligated into AscI digested pStart-K plasmid from the previous step. Ligated
plasmid was transformed into E. coli and grown on kanamycin selection plates. Plasmids from 8
colonies were extracted and the junctions were sequenced to confirm that the right insertion of
the Neo-cassette was present.

Figure 4. The insertion of a Neo-cassette after the ccl27 gene into the pStart-k plasmid by cut and
paste using the AscI restriction sites. This picture was modified from Wu, et al., 2008.
Insertion of a negative selective marker by gate-way recombination
Negative selection can greatly increase the efficiency of the screening process by
eliminating those colonies resulting from random insertion. Herpes simplex virus thymidine
kinase was used as a negative selection marker. Plasmid pWS-TK6, which contains the negative
selection marker, was kindly provided by the Capecchi lab (University of Utah). The gateway
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recombination kit was purchased from Invitrogen. Following the kit instructions, incubation of
the pStart-K plasmid with pWS-TK6 resulted in a gene swap between attL1/attL2 and
attR1/attR2. Successful recombination colonies were selected on ampicillin-containing plates.
Colonies were then retrieved and a large quantity of plasmid (~500 µg) was prepared by using a
QIAGEN plasmid Midi kit.

Gene targeting in mouse ES cells by electroporation
In conjunction with the laboratory of Dr. Jeffery Barrow, two tubes of prepared ES cells
at a concentration of 1.3E7/0.8 ml were freshly grown. An aliquot of 30 µg of FseI digested
targeting vector and 0.8 ml of cells were added to a 4mm cuvette and mixed well.
Electroporation was performed at 220 v, 500 µF. A control cell without DNA was also
performed. Electroporated cells were grown and screened by using the positive and negative
selection drugs as described in the protocol (Wu, 2008). 96 colonies were picked up and grown
on two 48-well plates. Replicate plates were made. One was frozen at -80°C and the other was
used for genomic DNA extraction to find out which cell lines came from true recombination. ES
cell genomic DNA was then extracted as previously described (Wu, 2008).

Screening the ES cell clones by Southern blot and PCR
As described in the Wu protocol, southern blotting was performed to screen the knockout ES cells. Non-radioactive Digoxigenin-labeled probes were used. The template for the left
and right probes was PCR amplified and then labeled using a Roche Dig-DNA labeling and
detection kit (Roche Applied Science). The templates are about 1kb. The primers used for left
probe is: Forward-GGCTTTGCCTCCTTAAAGTTCTA, Reverse-
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CCACTCCACTGCTTGCTTTGATTTCAGTC. Primers for right probes are: ForwardGACTTTACCTGGGTCTGTTACTGG, Reverse-CTCCTCTGTAGAGCTGGAAAACTTG.
Genomic DNA was digested with BsrG1. Successfully targeted loci should contain an additional
BsrG1 site. Wild type DNA produces a 12 kb band with either the left or right probe. Mutants
with the homologous recombination produce three bands: a wild-type genotype band of 12 kb is
seen and 7.2 kb band for the left probe and 10.5 kb band for the right probe will exist if
homologous recombination has occurred in the correct place.
At the same time, screening for the correct insertion was also done through PCR. A
Roche long template PCR kit was used. The PCR reaction was set up and the Mg2+ concentration
varied from 0.8 mM ~1.6 mM as described in the manual (Roche applied science). Two pairs of
primers were used for each arm. Primers for the left arm were: Forward 1CAACTCCCACAAAACAGCTCCACCC, Forward 2-GGGTACCAAGTGTCCAAATCCCCG,
Reverse 1- CTGGGTGCTCAGGTAGTGGTTGTCG, Reverse 2CGATGGGGGTGTTCTGCTGGTAGTG. Primers for the right arm were: Forward 1GACGTAAACGGCCACAAGTTCAGCG, Forward 2CTACGTCCAGGAGCGCACCATCTTC, Reverse 1- GCGGGCTGATGCAGATTCTTCTACG,
Reverse 2- GTGCCCTTTTCTGTCCTTCCTGCTG.

Morulae aggregation and embryo implantation
Following confirmation of appropriate recombination events via southern blot or PCR,
cell lines were thawed and cultured in ES medium until they were ready for aggregation.
Superovulation female mice were mated with male mice and morulaes were collected 2.5 days
thereafter by cutting and flushing the oviducts. Each morula was placed into a divot in a petri
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dish. Clusters of 4-12 ES cells were added to each divot. A total of 50-100 good morulaes were
used. After a few hours of incubation, the merged morulae (checked for aggregation by
dissecting microscope), were surgically implanted into the uterine horns of the pseudoimpregnated female, which was induced by mating with vasectomized males.

Chimeric, heterozygous, and homozygous mice generation
According to the protocol we followed, after the chimeric mice are born and reach sexual
maturity, the males mate with females to produce germline heterozygous pups. The heterozygous
mice would then be crossed to produce homozygous knockout mice.

Genotyping
PCR assays were to be used to genotype the knockout mice. Primers that used to identify
WT mice are, F-Wild, ATTCTAGAAGGTGGAGACACGTCC. R-Wild,
ACTCCAGGTAGCCTGGTGCTCAAAGG. Primers for knockout mice identification are, FWild (the same as wild type). R-KO, TGCGCTCCTGGACGTAGCCTTC. Wild type mice show
amplification of a 450 bp size band. For knockouts, a 760 bp size band is amplified.

Results

Targeting vector construction
Retrieving ccl28 gene
Part of ccl28 gene including exon 2, was pulled down from BAC Fosmid by
recombination as described in the Methods. The left homologous arm is 5.2 kb and the right
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homologous arm is 4.5 kb. The plasmid pStart-K used for homologous recombination is 2.7 kb.
A plasmid with a size of 12.4 kb is expected after extraction of the plasmids from the colonies
grown on kanamycin selective plates. Two plasmids were chosen to run in the gel (Figure 5).
The junction regions of the plasmids were also sequenced for further confirmation that the
correct sequence was obtained.

10 kb

Figure 5. Gel electrophoresis of plasmids which captured ccl28 through homologous
recombination. The left two lanes are plasmids extracted from two different colonies. The third
lane is the DNA ladder (BioLabs 2-log DNA ladder).
Replacing ccl28 exon 2 with ccl27-chloramphenicol
CCL27-chloramphenicol fusion gene was made by PCR as described in the Methods.
Homologous arms (50bp) identical to the border regions of CCL28 exon 2 were added to the
ends of the fusion gene. Colonies grown on chloramphenicol selective plates were picked and
grown and their plasmids were extracted and run on a gel (figure 6). Plasmids with the right
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recombination are 13kb. Recombination junction regions were also sequenced to confirm that the
correct sequence was obtained.

10 kb

Figure 6. Gel electrophoresis of plasmid DNA after replacement of ccl28 exon 2 with ccl27
through homologous recombination. The right-most lane is the DNA ladder (BioLabs 2-log
DNA ladder), and all the other lanes are plasmids extracted from different colonies.
Insertion of the positive selection marker
Insertion of the positive the selection marker into the constructor was done by the cutpaste method. Plasmid pEGPpA-ACN and pStart-K with ccl27 were cut with AscI. EGFP
fragment of the plasmid pEGFPpA-ACN was inserted into plasmid pStart-K by ligation. The
plasmid was then transformed into E. coli and grown on kanamycin selection plates. Colony
PCR was done to select for the plasmids that had the insertion in the right orientation. As shown
in the following figure, the samples showing a band have the insertion with the right orientation.
These plasmids were also confirmed by sequencing of the ligation junctions.
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1 kb
0.5 kb

Figure 7. Gel electrophoresis of the colony PCR products to confirm the insertion of the positive
selection marker. The right-most lanes are DNA ladders (BioLabs 2-log DNA ladder), and all the
other lanes show PCR amplification results using plasmid templates extracted from different
colonies.
Insertion of the negative selection marker
The negative selection marker was inserted by gateway recombination. Successful
recombination colonies were selected on ampicillin LB plates. Plasmids were extracted. Four
colonies were picked up and plasmids were extracted. As shown in figure 8, all picked colonies
had the correct recombination. The junctions were confirmed by sequencing.

Screening out the ES cells with the homologous recombination
Genomic DNA extracted from the ES cell colonies was subjected to southern blot and
PCR to identify the ES cells with the correct homologous recombination event. Non-radioactive
probes for southern blot did not work well. However, the PCR screening method consistently
worked. Figure 9A shows the PCR amplification products of the wild type ES cell DNA from
two different PCR conditions. The first condition was chosen as the PCR condition to be used for
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all the other samples. 18 ES cell colonies were confirmed by PCR to have the right homologous
recombination event, as shown in Figure 9 B and C, represented by those lanes having the
amplification band.

10 kb

Figure 8. Gel electrophoresis of plasmid DNA after gateway recombination to detect the
insertion of the negative selection marker. The right-most lane is the DNA ladder (BioLabs 2-log
DNA ladder), and the other lanes are plasmids extracted from different colonies.

Morulae aggregation and chimera production
This project was aimed at developing a mouse line that would express no endogenous
CCL28 but rather express the non-antimicrobial CCL27 under control of the CCL28 promoter.
This would theoretically have resulted in a mouse in which the CCR10 receptor-bearing
lymphocytes would traffic normally to all tissues but have none of the CCL28-mediated
antimicrobial activity. Such a mouse would be a powerful tool in understanding the role of
CCL28 as a component of the innate immune system. Unfortunately, although the construction
of the constructs and ES cell knockout worked perfectly, morulae implanted pseudo-impregnated
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females have not produced any chimeric pups. We feel it is beyond our current capabilities to
complete this project without extensive corporation with another lab.

10 kb
8kb

A

B

C

Figure 9. Gel electrophoresis of the PCR products for confirmation of the right homologous
recombination ES cells. The right-most lanes of all the panels are loaded with DNA ladder
(BioLabs 2-log DNA ladder). A, WT ES cell DNA was used to for long PCR amplification. The
left-most lane represents the condition (1.6 mM Mg2+ concentration) that amplified the long
target fragment successfully, while the middle lane did not (0.8 mM Mg2+ concentration). Panels
B and C are representatives of PCR amplification results through the use of left border primer or
the right border primer, respectively.
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Chapter 5: Discussion and conclusions

This research project focused on the study of the antimicrobial activity of the chemokine
CCL28. The structure-function relationship, killing mechanism and in vivo binding of the
chemokine have been all explored in this study. This work has improved our understanding
about the antimicrobial mechanism of chemokines and their contribution to direct innate immune
protection.
The first goal of this project was to explore the antimicrobial determinants of CCL28 at
the amino acid sequence level. Using protein mutation and recombination techniques, we have
compared the antimicrobial activity of different mutants of CCL28 protein. Our findings indicate
that C-terminal positively-charged amino acids are the major functional elements for the
antimicrobial activity of CCL28, although full length protein is optimal for the maximum
antimicrobial activity. Based on the result that full activity is only achieved when the full length
sequence is used, it would be interesting to further investigate the role of the N-terminus in the
antimicrobial activity of the protein. Hydrophobic amino acids have been considered important
players in helping AMPs insert into the bacterial membrane. In the future, the significance of
those hydrophobic amino acids should also be examined.
Although we have shown that disruption of the disulfide bonds does not affect the
antimicrobial activity of CCL28, obtaining its tertiary structure might be required to elucidate the
structure-function relationship in CCL28 and further provide guidance to generate specific
mutants for study. As CCL28 is a relatively small protein, it should not be difficult to determine
its tertiary structure. This could be an important research direction in the future. Importantly,
some AMPs that are found to be unstructured in aqueous state, are found to be structured only
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after interaction with an organic state (Mani, Cady et al. 2006; Campagna, Saint et al. 2007;
Lourenzoni, Namba et al. 2007). Determining CCL28 structure, as well as its predicted structure
when interacting with a bacterial membrane, could be another important avenue for future
research.
The structure-activity analysis in this study contributes to the understanding of the
antimicrobial mechanism of CCL28. The antimicrobial mechanism for other conventional
cationic AMPs has been proposed to be charge-mediated, in which the positively charged AMPs
and the negatively charged microbial membranes interact with each other. We have provided
evidences that the chemokine CCL28 likely uses a similar mechanism for its antimicrobial
activity. This conclusion is based on several independent observations. First, by using confocal
fluorescent microscopy, I have observed that CCL28 binds to S. typhimurium phoP bacteria, but
the highly similar, non-antimicrobial, chemokine CCL27 does not bind bacteria (data not shown).
The CCL27 chemokine has been shown to lack the extended C-terminus of CCL28, which is
highly positively charged. Second, mutant bacterial strains, such as phoP S. typhimurium and Y.
pestis strains, which don’t have the ability to reduce the negative charges on their membranes,
are more sensitive than their wild type parent strains to CCL28-mediated cell death. Third,
CCL28 binds and kills phoP S. typhimurium better in low salt concentrations than in high salt
conditions. These three observations all support the conclusion that CCL28 shares many
similarities with other better studied conventional AMPs.
It has generally been accepted that the antimicrobial activity of AMPs is receptorindependent; however, there is evidence suggesting that specific microbial proteins, including
antimicrobial chemokines, could be actively involved in the process of AMP bacteria recognition
(Li, Sun et al. 2006; Crawford, Lowe et al. 2011). It is quite possible that in addition to simply
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recognizing the negatively charged phospholipids of the bacterial membrane, other bacterial
components may be involved in AMP recognition of microbes. Our results provide evidence to
support this proposition. For example, we have shown, by counting the number of bacteria bound
by CCL28 and the level of CCL28 binding on each bacterium, that high salt concentrations
decreased the intensity of CCL28 binding to bacteria but not the percentage of cells bound. The
charge could mediate the initial binding of chemokine to bacteria, but when bacterial cells have
swelled in the low salt solution, it may result in increased CCL28 binding to the membrane.
Swelling of bacterial cells may also expose their other membrane proteins which may interact
with CCL28. This interaction between CCL28 and bacteria could be specific for the
antimicrobial chemokine CCL28, but not for the non-antimicrobial chemokine CCL27, since we
have observed that CCL27 does not bind to bacteria (data not shown). Additionally, bacteria
killing by AMPs in low salt conditions may be augmented by osmosis-assisted rupture, since we
have observed that there was more GFP leakage when bacteria were treated with CCL28 under
low salt concentration (data not shown).
To definitively understand the antimicrobial role of CCL28 in vivo it may be necessary to
generate a transgenic mouse model. In our attempts to do this we have successfully constructed
an appropriate vector and knockout ES cells have been successfully generated. However, the
subsequent generation of chimeric mice didn’t work for our collaborators. In the near future, the
construct will be sent to commercial knockout mouse center to obtain chimeric mice. It is
anticipated that in the future the use of such a model, where CCL27 is substituted for CCL28,
could provide definitive answers to the in vivo role of CCL28 in modulating bacterial numbers or
communities. In an effort to circumvent the challenges of constructing a transgenic mouse line
we also explored the idea of using antibody-mediated chemokine inactivation to examine the role
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of CCL28 in vivo. These studies confirmed that through the addition of exogenous CCL28 it was
possible to increase binding of CCL28 on commensal bacteria as well as Salmonella bacteria.
We then confirmed that endogenously produced CCL28 efficiently bound to commensal bacteria.
Finally, in an effort to determine if these levels of binding resulted in in vivo bacterial cell death
we tried to block chemokine activity by feeding polyclonal antibody to mice and then tracking
Salmonella numbers in the animal. Although these experiments resulted in findings which were
suggestive of an in vivo role for the chemokine in protecting the stomach from Salmonella
colonization there was a high degree of variability resulting in no statistical differences in these
experiments.
In summary, in the course of this work I have conducted experiments in which I have
constructed a large panel of mutant versions of the chemokine CCL28. Using these mutants I
have demonstrated that positively-charged amino acids in the C-terminal end of the chemokine
play an indispensable role in mediating microbial cell death in both Gram-positive and Gramnegative bacteria. This study, published in the European Journal of Immunology, represents the
first molecular dissection of the antimicrobial activity of any chemokine. In addition, my work
has shown that CCL28 binds bacteria in both high and low salt concentrations in vitro with most
efficient binding occurring at 20 mM NaCl concentrations. Furthermore, I demonstrated that
CCL28 produced within the murine gastrointestinal tract is at high enough concentrations to
efficiently bind commensal bacteria within the murine large intestine. All of these studies
suggest that CCL28 may play an important in vivo role in controlling bacterial numbers at
mucosal surfaces. In an effort to definitively determine if CCL28 serves an important role in
vivo, I have designed and constructed a molecular construct to make a transgenic mouse which
would express the non-antimicrobial CCL27 under the promoter of the antimicrobial CCL28
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gene. Such a transgenic animal would theoretically traffic CCL10 bearing lymphocytes
effectively to mucosal surfaces but not play a direct role in innate immune protection of the
animal, making it an ideal model to study the antimicrobial properties of CCL28 in vivo.
Although this project is not yet completed I have generated ES cells which can be used to
generate chimeric mice in the future.
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